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Abstract
Polybrominated Diphenyl Ethers (PBDEs) are flame retardants widely used within the
United States in various products such as plastics, electronics, textiles and furniture. With an
increase in production and usage, PBDEs have recently emerged as a contaminant of concern. Due
to their chemical structure, PBDEs have the propensity to bioaccumulate in mammals. In fact,
elevated PBDE concentrations have been recorded in human breast milk. Due to the potential
widespread exposure to PBDEs, this study investigates human blood concentrations of PBDEs
generated through the 2003-2004 National Health and Nutrition Examination Survey. Through the
use of statistical modeling, a comparison of mean PBDE concentrations in ng/g lipid is conducted
based on age, gender and ethnicity. From a sample of 2337 individuals, the average blood
concentration of PBDEs was approximately 81 ng/g lipid. The average PBDE concentration of
males was significantly higher than females, using a 95% confidence level. In addition, PBDEs
detected in human blood ranged approximately from 0.05 to 3676 ng/g lipid, with the highest
concentrations found in black males. Also, a logistic regression analysis is conducted to determine
whether an increase in background PBDE concentrations is a risk factor for obesity. Furthermore,
the analyses of PBDEs are repeated for phthalates and polychlorinated Biphenyls for comparison.
Finally, the measured concentrations of PBDEs are also compared to health outcome data known
to show potential risk.

xiv

Chapter 1
Introduction
1.1 Flame Retardants
In 2009, the National Fire Protection Association reported an estimated 1,348,500 fires in
the United States. These fires were responsible for approximately 17,050 civilian injuries, 3,010
civilian deaths and over $12 billion in property damage. Many of the casualties included children
and the disabled. Unfortunately, the various threats of fires have always been a concern throughout
history (American Chemistry Council, 2017). As a result, fire protection is a very important aspect
of emergency planning. There are various methods of fire response and prevention. Within the
United States, many entities share a responsibility to protect citizens from fire hazards. A city fire
department is a popular example. However, a lesser-known yet very impactful entity includes the
chemical industry. For many decades, the chemical industry has been responsible for generating
compounds combat the progression of fire. These chemicals are called flame retardants (United
States Environmental Protection Agency [USEPA], 2014).

The term “flame retardant” does not refer to a group of chemicals but, instead, refers to a
function. Some chemicals with varying structures and properties can function as flame retardants
and are sometimes combined for greater effect (American Chemistry Council, 2017; ATSDR,
2017; USEPA, 2014). Flame retardants are usually described as inorganic, halogenated
compounds often containing bromine, chlorine, phosphorus or nitrogen. By lacing various
consumer goods with flame retardants, the progression of fire is delayed or prevented. Generally,
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ignition is prevented by increasing the threshold necessary to start a fire which delays flashover
and reduces the spread of fire (American Chemistry Council, 2017).

Flame retardant use is an innovative way to protect ourselves from injury, death and
prevent property damage. It is important to note that over three decades ago, American residents
had approximately seventeen minutes to escape a house fire, while today, residents have three to
four minutes. This is largely due to the types of materials used to build today’s household furniture
in comparison to thirty years ago. Then, more natural materials were used while today’s furniture
contain more synthetic material that are more flammable (Davis, 2016). This further accentuates
the need for flame retardants in today’s household goods.

The first flame retardants used in the United States were polychlorinated biphenyls (PCBs).
However, due to human health concerns, PCB production was banned in 1979. PCBs have been
classified as carcinogenic to humans (group 1) by the International Agency for Research on Cancer
(IARC) and are known as persistent organic pollutants. As a result, PCBs were replaced as flame
retardants by a compound with similar properties known as polybrominated diphenyl ethers
(PBDEs) (Vonderheide et al., 2008). After 1979, PBDE compounds were the major group of flame
retardants due to their cost effectiveness. In recent years, there has been a growing concern
pertaining to the potential environmental and public health risks of background PBDE levels
(Alaee et al., 2003; Aylward et al., 2013; Banasik et al., 2009; Birnbaum et al., 2004; Castorina et
al., 2011; Turyk et al., 2009; Vasiliu et al., 2006).
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1.2 Polybrominated Diphenyl Ethers
Polybrominated diphenyl ethers are flame retardants used in a variety of appliances,
fixtures, furniture and other household goods. The use of these chemicals has increased
tremendously since the ban of PCBs. Just as PCBs and PBDEs share similar flame retardant
properties, they also share similarities in chemical structure. PBDEs are not covalently bonded to
the polymer matrix within materials in which they are used. Therefore, these brominated
compounds are known to readily leach into the surrounding environment where they have shown
resistance to various forms of biodegradation. They have been shown to bioaccumulate in the food
chain (Costa & Giordano, 2007; Kiviranta et al., 2004; Turyk et al. 2015; Viberg et al., 2003).
Lower brominated congeners tend to be more persistent and bioaccumulate more than higher
brominated congeners. BDE congeners differ in the orientation or total number of bromine atoms
attached to the ether molecule (ATSDR, 2017).

There are 209 possible congeners. Of these, BDE-47 and BDE-99 make up 75% of the total
brominated flame retardants in commercial mixtures. In comparison to BDE-47, there is twice as
much BDE-99 in these commercial mixtures. When congeners contain the same number of
bromine atoms, they are referred to as homologs. There are ten homologous groups of PBDEs;
three of which are produced commercially. These three homologs are: decabromodiphenyl ether
(decaBDE), octabromodiphenyl ether (octaBDE) and pentabromodiphenyl ether (pentaBDE).
DecaBDE has been the most widely used homolog worldwide (USEPA, 2014).

At the end of 2004, pentaBDE and octaBDE mixtures were voluntarily phased out by their
only U.S. manufacturers. According to the Environmental Protection Agency, as of January 2014,
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PBDEs are no longer produced nor imported in the United States (ATSDR, 2017). However, levels
of PBDEs in breast milk have significantly increased in the United States. In fact, just as usage of
PBDEs continued to increase, so did the average concentration of PBDEs in humans. The latter
occurs because PBDEs remain ubiquitous in various products, especially in indoor environments.
Thus, despite being no longer produced or imported, PBDEs will persist for many years in our
environment. In addition, PBDEs will likely be present in human tissue and body fluids at elevated
levels for years to come (Darnerud et al., 2001; Frederiksen et al., 2009; Hooper & McDonald,
2000; Schecter et al., 2003).

Due to the relatively elevated levels of PBDEs found in human breast milk, in comparison
to other regions such as Europe (e.g., France, Germany, and Russia), there is increasing concern
for pregnant mothers and nursing children as they may be more vulnerable to potential health
effects of PBDEs, which are known to disrupt the body’s endocrine system and thyroid hormone
levels (Darnerud et al., 2001). Since they are lipophilic, PBDEs tend to accumulate in human fatty
tissues (USEPA, 2014). As a result, it is important to investigate the level of association between
their background concentrations and obesity. An investigation of the concentration and distribution
of PBDEs in the American population is critical to characterizing levels of risk per demographic
category.

1.3 Phthalates & Dioxin-Like Polychlorinated Biphenyls
There are dioxin-like and non-dioxin-like PCBs. Non-dioxin-like PCBs are often referred
to as indicator-PCBs and include some mono-ortho-substituted biphenyls. Some PCBs are
described as dioxin-like chemicals because they act in the body through similar mechanisms as
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dioxins (ATSDR, 2000). As previously mentioned, PBDEs and PCBs (especially dioxin-like
PCBs) share key similarities including their flame retardant properties and chemical structures.
However, they also share other attributes along with phthalates. While American PBDE production
and importation have reportedly ceased, and although PCBs have been banned in the United States,
phthalates are still in use (ATSDR, 2000; ATSDR, 2002; ATSDR, 2017). Like PBDEs and dioxinlike PCBs (dl-PCBs), phthalates are ubiquitous in our surroundings. Phthalates are used in
detergents, adhesives, lubricating oils, plastic clothing, containers and personal-care products, just
to name a few (ATSDR, 2002). All three compounds can be found in household dust. Therefore,
we are constantly exposed to these chemicals. In addition, PBDEs, dl-PCBs and phthalates are all
known as potential endocrine disrupting compounds and are lipophilic. All three compounds have
garnered significant attention concerning their potential human health effects (ATSDR, 2000;
ATSDR, 2002; ATSDR, 2017; Aylward et al., 2013). Although this research primarily focuses on
characterizing exposure levels and potential human health effects of PBDEs, it is also pertinent to
compare results of PBDE analyses with those of PCBs and phthalates. The differences and
similarities of these results will be discussed.

1.4 Objectives
This research study investigates the distribution of Polybrominated Diphenyl Ether
concentrations in American blood using various demographic attributes through the 2003-2004
National Health and Nutrition Examination Survey (NHANES). The objectives of the current
study are comprised of the following:
o Characterize the background concentrations of PBDEs in the blood of 2003-2004
NHANES participants.
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o Compare the PBDE blood concentrations between various demographic groups
including genders, age groups, ethnicities; and, genders and ethnicities (e.g., Black
Males vs. Mexican American Females).
o Since PBDEs have a strong affinity for lipids and bioaccumulate in human adipose
tissue, investigate their association with obesity.
§

Similarly, the association between PBDE concentrations and being
overweight is also investigated.
•

Repeat analyses for other lipophilic compounds including phthalates
and dioxin-like PCBs.

•

Discuss results for the aforementioned objectives in relation to those
of phthalates and dioxin-like PCBs.

PBDEs are a relatively new compound whose usage significantly increased over time
(ATSDR, 2017). Much research remains to be done to fully understand their characteristics,
distribution and potential human health effects. Therefore, these findings will provide a
significant contribution to the overall body of knowledge for PBDEs.

1.5 Hypotheses
According to the objectives of this study, the following hypotheses will be tested:
1. Biomonitoring data obtained from the National Health and Nutrition Examination
Survey indicates the presence of background biomarkers of PBDE, dl-PCB, and
phthalate exposure in individuals from a sample of the general population.
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2. Due to the bioaccumulative properties of PBDEs in the human body, increasing
PBDE concentrations are significantly associated with increasing with age groups.
a. Due to the bioaccumulative properties of dl-PCBs in the human body,
increasing dl-PCB concentrations is significantly associated with increasing
with age groups.
b. Due to the bioaccumulative properties of phthalates in the human body,
increasing phthalate concentrations is significantly associated with
increasing with age groups.
3. Since PBDEs are ubiquitous in the environment, the average concentrations of its
biomarkers are homogeneous across other sample subgroups including genders,
ethnicities, and, genders and ethnicities; indicating that these subgroups are not at
an increased risk of a negative health outcome.
a. Similarly, average dl-PCB concentrations are homogeneous across other
sample subgroups including genders, ethnicities, and, genders and
ethnicities; indicating that these subgroups are not at an increased risk of a
negative health outcome.
b. Similarly, average phthalate concentrations are homogeneous across other
sample subgroups including genders, ethnicities, and, genders and
ethnicities; indicating that these subgroups are not at an increased risk of a
negative health outcome.
4. Blood sample data from the National Health and Nutrition Examination Survey
reveal that the background concentrations of PBDEs do not significantly increase
the odds of obesity nor the odds of being overweight.
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a. Blood sample data from the National Health and Nutrition Examination
Survey reveal that the background concentrations of dl-PCBs do not
significantly increase the odds of obesity nor the odds of being overweight.
b. Blood sample data from the National Health and Nutrition Examination
Survey reveal that the background concentrations of phthalates do not
significantly increase the odds of obesity nor the odds of being overweight.
5. Due to the similarities of PBDEs and dl-PCBs, average concentrations are not
significantly different among demographic categories.
a. Although distributions of phthalate concentrations can be discussed in
relation to PBDEs, specific comparisons cannot be made due to a difference
in measurement units (ng/g lipids for PBDEs and dl-PCBs vs. ng/mL for
phthalates).
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Chapter 2
Literature Review
2.1 Brominated Flame Retardant Use
The use of PBDEs began in the late 1970s. Their commercial production began largely as
a response to the ban of PCBs, which were also used as flame retardants. Due to mounting
environmental health concerns, PCBs were no longer produced in the United States. As a result,
the production and usage of other flame retardants such as PBDEs became more prevalent. In fact,
since the ban of PCBs, there has been a significant augmented use of PBDEs (ATSDR, 2017). In
2001, the global production rate of PBDEs was over 67,000 tons per year, as shown in Table 1
(Birnbaum, & Staskal, 2004). By 2003, approximately 98% of the global demand for pentaBDE
occurred in North America (Hale et al., 2003). However, largely due to unsubstantiated public
health concerns, PBDEs are also no longer in production in the United States. At the end of 2004,
the only manufacturers of pentaBDEs and octaBDEs voluntarily phased out their production. As
the only remaining PBDE mixture marketed for commercial products, decaBDEs experienced a
similar fate. The only American manufacturers of decaBDEs were Albermarle Corporation and
Chemtura Corporation; and their largest importer was ICL Industrial Products, Inc. In 2009, all
three companies guaranteed a voluntary phase out of PBDE manufacture and importation for
nearly all uses in America by December 31st of 2012. They also guaranteed a complete phase out
of manufacture and importation for all uses of PBDEs in America by the end of the year 2013
(ATSDR, 2017).
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Table 1. Major Brominated Flame Retardant Volume (metric tons) estimates by region in 2001
(Birnbaum & Staskal 2004).

During periods of production, PBDEs were used as flame retardants in a variety of
materials including thermos plastics. PBDEs were physically added to these materials instead of
being chemically combined. Since PBDEs were not covalently bonded to many of the materials
they were used for, these chemicals could easily diffuse out of the materials (Siddiqi et al., 2003).
The furniture industry found great use in pentaBDEs as flame retardants (Standen, 2013). In fact,
over 95% of pentaBDE commercial mixture usage was in furniture. Specifically, pentaBDEs were
predominantly used in flexible polyurethane foams which are found in mattresses, sofas, carpets,
etc. The majority of furniture treated with pentaBDEs were sold in California (ATSDR, 2017). It
is the only state that required, by law, that upholstered products contain an approved level of
ignition resistance (Standen, 2013). Only a small percentage of pentaBDEs were used for other
materials like adhesives, printed circuit board components, hydraulic fluids, and rubber products.
OctaBDEs were predominantly used as flame retardants in the plastic industry and specifically for
acrylonitrile-butadiene-styrene terpolymers, often used in computer monitors and casings.
DecaBDE mixtures were used as additive flame retardants for many polymer applications. The
primary use of decaBDEs was high impact polystyrene often used as cabinet backs in the television
industry (ATSDR, 2017; Watanabe & Sakai 2003).
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2.2 Regulations & Guidelines
Although PBDEs are no longer being produced or imported in the U.S., the relatively
limited US regulations and guidelines continue to apply since many products currently used still
contain PBDEs. The Occupational Safety & Health Administration (OSHA) has not formulated
any occupational regulations for these flame retardants. The US Food & Drug Administration
(FDA) has not set any allowable bottled water limits for PBDEs. Also, the International Agency
for Research on Cancer (IARC) has classified PBDEs as Group 3 toxicants - not classified as
human carcinogens (Standen, 2013). The Agency for Toxic Substances and Disease Registry
(ATSDR) has generated Minimum Risk Levels (MRLs) for these brominated flame retardants.
Based on a no-observed-adverse-effect-level for thyroid hormone effects in rats, an intermediateduration inhalation MRL of 0.006 mg/m3 has been generated for lower-brominated congeners.
Also, based on a lowest-observed-adverse-effect-level for endocrine effects in female rats, and
neurobehavioral and reproductive effects in F1 offspring from several reports, the ATSDR has
derived an acute-duration oral MRL of 0.00006 mg/kg/day for lower-brominated congeners
(ATSDR, 2017). Moreover, based on a negligible lowest-observed-adverse-effect-level for
decreased testosterone in rats, an intermediate-duration oral MRL of 0.000003 mg/kg/day was
generated for lower-brominated PBDEs. The ATSDR has also derived an acute-duration oral MRL
of 0.01 mg/kg/day for decaBDE due to a no-observed-adverse-effect-level for neurobehavioral
health effects found in rats. In addition, based on a negligible lowest-observed-adverse-effect-level
for increased serum glucose found in a study of rats, an intermediate-duration oral MRL of 0.0002
mg/kg/day was derived for decaBDE (ATSDR, 2017; Standen, 2013). The Environmental
Protection Agency (EPA) has not assigned a reference concentration (RfC) for PBDEs. The EPA
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has not generated drinking water standards for PBDEs. Instead, the US EPA has generated
reference doses (RfDs) for PBDEs. The following are the current RfDs for BDE congeners. (IRIS,
2003; IRIS, 2004; IRIS, 2008a-d).
•

Penta-BDE: 2x10-3mg/kg/day (IRIS, 2004)

•

Octa-BDE: 3x10-3mg/kg/day (IRIS, 2003)

•

Deca-BDE: 7x10-3mg/kg/day (IRIS, 2008a)

•

2,2’,4,4’-tetraBDE: 1x10-4mg/kg/day (IRIS, 2008b)

•

2,2’,4,4’,5-pentaBDE: 1x10-4mg/kg/day (IRIS, 2008c)

•

2,2’,4,4’,5,5’-hexaBDE: 2x10-4mg/kg/day (IRIS, 2008d)

For all RfDs, potential effects to the nervous system is of significant concern, with a
potential for neurobehavioral health effects; despite a relatively low level of confidence. Finally,
mono-BDE congeners are regulated under the Comprehensive Environmental Response,
Compensation, and Liability Act and Resource Conservation and Recovery Act (ATSDR, 2017).

2.3 Exposure Assessment
An exposure is defined as an interaction with the skin or eyes or contact through breathing
or swallowing. This contact can be short-term or acute. On the other hand, it can also be long-term
or chronic. It should be remembered that an exposure is only an opportunity for absorbing a
substance. The types and duration of an exposure are key determinants of a significant dose. Then,
if this dose is significant, there may be a health effect. Exposure assessment is the process of
determining how someone may come into contact with a toxicant by considering the exposure
route, frequency, duration and amount of the toxicant. There are several assessment methods which
depend on the kind of exposure in question. Exposure assessments are commonly used in
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environmental and occupational settings (Aylward et al. 2013; Lebeau, 2012). Passive air sampling
may be conducted in a rural environment to evaluate environmental air quality (Jaward et al. 2005).
In occupational settings, exposures to toxicants may be assessed through biomonitoring which
measures the body burden of toxicants and their metabolites through the analysis of human fluids
(e.g., blood) (Lebeau, (2012).

2.4 Biomonitoring
Biomonitoring is the process of determining the presence of chemicals in the human body
as a result of an exposure. Once a chemical has been absorbed due to an exposure to food, air
water, dust, etc., and depending on the pharmacokinetics of the chemical, it may be measured in
various biological media. These commonly include the sampling of urine, blood, breast milk,
tissue, etc. The chemicals being analyzed in biological media are often referred to as biological
markers. Measurable concentrations of the parent chemical and its intermediate or conjugate
allows for the prediction of a human health effect (Centers for Human Health Assessment, 2017).
A measured chemical concentration can also be used to determine previous health effects based
on current levels in the body (Centers for Human Health Assessment, 2017; Lebeau, 2012). Their
concentrations can be used to identify early physiological changes. In addition, based on key
metabolic characteristics of certain individuals, biological markers can be used to determine health
effects, given a level of exposure. Although, the presence of a chemical in a biological sample
does not automatically indicate a health effect (Ames et al., 1990a,b).

In the process of biomonitoring, there are at least three factors that affect the detection of
biological markers; one of which is half-life. Each chemical has a half-life, which is the time it
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takes for a concentration of a chemical to decrease by half in the human body. If the chemical has
a relatively brief half-life of one day, it is imperative to analyze the biological samples as quickly
as possible. Thus, one must be aware of a chemical’s half-life, as it is a key consideration in
biomonitoring results. Other factors that affect the detection of biological markers include the
physical characteristics of the chemical and the detection limits of the instrument being used
(Aylward et al., 2013; Centers for Human Health Assessment, 2017; Lebeau, 2012).

As previously mentioned, there are various uses for biomonitoring. Biomonitoring is used
to determine environmental (indoor or outdoor) and occupational exposures to toxicants. At the
crux of biomonitoring is the need to understand if a population is at-risk after a chemical exposure.
Thus, in the occupational setting for instance, biomonitoring is crucial if workers tend to work
with chemicals at levels that are known to cause injurious health effects. Baseline levels of
toxicants may be recorded for a group of workers. Over time, biological samples are taken from
the workers on a routine basis. This allows us to determine whether concentrations of toxicants
have increased significantly and may lead to a health effect (Lebeau, 2012).

On a regional or national level, biomonitoring serves as an important tool to gauge the
background levels of people among various American demographic categories. Public health
researchers use this biomonitoring data to determine if the reported levels of toxicants are
associated with various human health effects. An example of regional biomonitoring includes
studies of large populations in the Center for the Health Assessment of Mothers and Children of
Salinas (CHAMACOS) Study which is one of the longest running longitudinal birth cohort study
of pediatric environmental exposures in a farmer community (Castorina et al., 2011; Eskenazi et
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al., 2013). A similar study is the Health Outcomes and Measures of the Environment (HOME)
Study in Cincinnati, Ohio from March 2003 to February 2006 which investigated the human health
effects of low-level environmental toxicants (Vuong et al., 2015). On a much larger scale,
scientists refer to the National Health and Nutrition Examination Survey (NHANES) to analyze
biomonitoring data. NHANES biomonitoring data serves as the primary source of information for
this dissertation research (Centers for Human Health Assessment, 2017).

NHANES is administered by the Centers for Disease Control & Prevention’s National
Center for Health Statistics. This biomonitoring program was started in the early 1960s and
focused on specific populations and health topics (Centers for Human Health Assessment, 2017;
Lebeau, 2012). In 1999, NHANES became a continuous biomonitoring program which changes
focus based on several health and nutrition measurements that address emerging needs. A
nationally representative sample of few thousand people are surveyed every year. Participants are
from 15 counties throughout the country. NHANES data are released every two years. For
biomonitoring specimens, participants are 6 years or older. Blood specimens are gathered from
participants that are 12 years or older. It is important to note that the measured analytes cannot be
used to estimate regional levels such as cities or states. They also cannot be used to generate
estimates for populations with unusual exposures (Centers for Human Health Assessment, 2017).

2.5 Brominated Flame Retardant Exposure
2.5.1 Occupational Exposure
Polybrominated Diphenyl Ethers are ubiquitous in our environment because they are used
as flame retardants in a variety of materials. When considering the most at-risk populations as a
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result of their occupations, we must seriously consider workers involved in the production,
distribution, handling and disposing of materials that contain PBDEs. Naturally, e-waste workers
and dismantlers fit this category very well (Darnerud et al., 2001). According to Watanabe &
Sakai, in Japan, hazardous waste incinerators and final disposal sites are some key sources of
brominated flame retardant effluents (Watanabe & Sakai, 2003). Among disposed wastes,
televisions and computers may serve as significant sources of PBDEs. In comparison to
transportation materials, electrical appliances, building materials and others, electronics contained
over half of the relative amounts of flame retardants, as shown in Figure 1 (Darnerud et al., 2001;
Watanabe & Sakai, 2003). As a result, their research has shown that workers at electronicsdismantling facilities are among the most exposed individuals and appropriate measures should be
taken to protect them along with those that handle other similar consumer waste products
(Watanabe & Sakai, 2003).

Figure 1. Relative amounts of flame retardants (including PBDEs) in various sectors (Darnerud
et al., 2001).
Sjodin et al. conducted a study of PBDE levels among full-time workers at a computer
screen facility and clerks from an electronics-dismantling plant with hospital cleaners as the
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control group. Sjodin et al. reported significantly higher concentrations of PBDEs among workers
at the electronics-dismantling plant in comparison to hospital cleaners. Through this research,
despite the relatively small sample size, results suggest that those who handle computer parts may
have increased exposures to PBDEs (Sjodin et al., 1999). Also, BDE-47 was among the most
prevalent BDE congeners among workers according to a study of 52 office workers in Boston,
Massachusetts (Makey et al., 2016).

Another potentially at-risk group of people due to the activities in which they partake
include gymnasts. These athletes spend an inordinate amount of time with safety materials such as
pit cubes and landing mats, which help to brace their fall during exercise. Because of their flame
retardant content, materials used by gymnasts have been named as the primary culprits for the
abnormally high concentrations of PBDEs found in these athletes. Research has also shown that
apart from the materials, the facilities in which they train has been found to contain elevated levels
of flame retardants in air and dust (Carignan et al., 2016). Carignan et al. have shown that these
elevated levels of flame retardants corresponded with significantly higher concentrations of
pentaBDEs in the blood serum of gymnasts. Concentrations were also significantly higher after
practice in comparison to before practice, which suggests that elevated concentrations were likely
due to contact with materials and dusts within the facility. Approximately 89% of foam samples
from many training facilities contained flame retardants. Despite their interesting findings, this
study was based on a relatively small sample of 53 participants; thus, leading to a relatively low
statistical power (Carignan et al., 2016). However, it helps to identify another potentially at-risk
group due to a specific type of activity or occupation. In general, further research should be
conducted to determine the total PBDE body burden contribution of occupations in America.
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2.5.2 Residential Exposure
Unlike some regions of the world, the primary source of PBDE exposure in America is the
indoor environment; especially, residential exposure. It is difficult to discuss residential exposure
to PBDEs without considering the impact of California’s formerly strict flame retardant
requirements. In 1975, Governor Jerry Brown signed the “Technical Bulletin 117” into law
(Standen, 2013). This required all upholstered furniture to be injected with flame retardants like
PBDEs. Since then, this law became a de facto national standard. Recently, California’s Technical
Bulletin 117 has been revised. Beginning in 2014, on his most recent stint as California’s governor,
Mr. Jerry Brown signed a revision to this law which no longer requires the injection of flame
retardants into California’s furniture. However, prior to this revision, many studies investigated
the impacts of Technical Bulletin 117 on PBDE levels among American residents; especially
Californians (Standen, 2013).

An increase of approximately one order of magnitude was reported for indoor air and dust
concentrations of PBDEs in North America in comparison to Europe. The authors mention this
disparity is likely due to a difference in fire standards between the two regions (Frederiksen et al.,
2009). According to Castorina et al., on average, PBDE blood levels were approximately 20 times
higher in the US in comparison to Europe (Castorina et al., 2011). The total range of PBDE levels
in Americans was from 4.2 to 1380 ng/g lipid. The pentaBDE mixture was traced in over 97% of
samples. Researchers found that the total PBDE concentrations in Americans significantly
increased with the length of time someone has resided in the United States, and in women living
in Californian homes containing at least 3 pieces of stuffed furniture. Specifically, the possession
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of 3 or more stuffed furniture was significantly associated with nearly a 27% increase in women’s
blood concentrations of PBDEs (Castorina et al., 2011). A study by Harley et al. also indicated
that the strongest predictor of PBDE concentrations among pregnant women living in a lowincome mostly-Hispanic immigrant community in California, was residence time (Harley et al.,
2010).

Zota et al. investigated the impacts of California’s flammability standards. Comparisons
were made between PBDE levels in household dusts from Californian homes and those from seven
other regions in the United States. A significantly higher household dust level of PBDEs was found
in Californian homes compared to other regions in America. Investigators also reported
approximately a two-fold increase in blood serum concentrations of PBDEs; that is, a least square
geometric mean of 73.0 vs. 38.5 ng/g lipid (Zota et al., 2008).

Frederiksen et al. indicated that although foodstuffs with a high fat content had relatively
higher levels of PBDEs, diet alone cannot explain background levels of PBDEs among Americans.
It was determined that the ingestion of indoor dusts contributed to the highest intake of BDE-209.
Infants, often displaying crawling behaviors, tend to be exposed to a variety of chemicals. Toddlers
were found to have ingested a significantly higher amount of PBDEs from indoor dusts in
comparison to adults. Infants are also exposed to PBDEs via breast feeding. Overall, they have a
higher body burden in comparison to adults (Frederiksen et al., 2009).
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2.5.3 Dietary Exposure
Although diet is not the primary source of PBDE exposure in the United States, it remains
a significant source. In many regions of the world diet is the primary source of exposure. When
discussing diet, the main attribute of PBDEs to consider is their affinity to fat. Due to this
lipophilicity, research has shown that foods heavy in fat like poultry, meat, and fish (especially
from top predators) contain significantly higher levels of PBDEs in comparison to fruits and
vegetables. In general, average dietary PBDE levels follow this trend: vegetables ≤
dairy<meat<fish. The PBDE content of North American meat was generally higher in comparison
to other regions of the world (Frederiksen et al., 2009). Similarly, in a Finnish study of dietary
PBDE intake, Kiviranta et al. found that approximately 53% of PBDE intakes were from Fish.
These results were comparable to dietary PBDE intake studies in Sweden and Canada (Kiviranta
et al., 2004).

Fromme et al. investigated various sources of PBDE exposure among 27 healthy females
and 23 healthy males in Germany. Researchers found that dietary exposure was responsible for
97% of the average intake and 95% of the high intake of total PBDE intake in this adult population.
Their findings coincide with other studies that have shown that diet is a significant exposure source
in many European countries (Fromme et al., 2009).

Since Fish, especially top predators, are key dietary sources of PBDEs it is important to
note that some fish and marine organisms contain what Teuten et al. have determined to be
naturally produced PBDEs. The True’s Beaked Whale is one such organism. Studies of these
animals have found methoxylated polybrominated diphenyl ethers (MeO-PBDEs) which are
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structurally-similar to synthetic PBDEs. Through methoxylation processes the PBDEs become
MeO-PBDEs. Molecular-level C-14 analysis was used to determine the source of the halogenated
compounds (Teuten et al., 2005). For example, a change of C-14 value of +90 per mil shows that
the source was natural. On the other hand, a value of -990 per mil for Bromkal 70-5DE (a
commercial mixture of PBDEs) indicated that the source was industrial. Just like their
nonmethoxylated counterparts, MeO-47 and 68 showed a high propensity for bioaccumulation.
The most likely source of exposure of MeO-PBDEs for the whales is dietary (e.g., squid
consumption). Microorganisms also naturally produce these compounds and the authors suggest
that this may be a detoxification mechanism. The natural production of these compounds has been
occurring before any known environmental release of industrial PBDEs. In fact, cytochrome p450
and other enzymes used in the metabolism of these compounds are believed to have existed for
millions of years and probably arose originally as a response mechanism for naturally produced
compounds in the environment (Teuten et al., 2005).

2.6 Polybrominated Diphenyl Ether Health Effects
2.6.1 Acute
Acute human health effects after PBDE exposure is poorly understood and currently being
investigated. In general, most of the information related to acute health effects of PBDE exposure
is from animal studies. Thus far, in animals, decaBDE mixtures have been shown to be relatively
less toxic in comparison to lesser-brominated BDE congeners. In humans, decaBDEs are expected
to have very little health effect. This is due to its much different toxicity in comparison to lesserbrominated congeners (ATSDR, 2017).
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In animals, one of the most significant health endpoints has been PBDEs’ potential effect
on thyroid hormones. For example, rats and mice who were fed food laced with moderate amounts
of lesser-brominated congeners for short periods had predominantly thyroid-related effects.
However, it should be noted that thyroid disruption due to, short-term, small-to-moderate amounts
of PBDE exposure is thought to be species-dependent. As a result, this suggests that similar effects
are less likely to occur in humans. In addition, testing of animal offspring has also shown
behavioral effects due to acute PBDE exposure (ATSDR, 2017). Once again, these behavioral
effects are believed to be a result of changes in the thyroid since it is a major determinant of nervous
system development. No additional birth defects have been recorded in animals after acute
exposure. Much research is needed to determine if acute PBDE exposure has any reproductive
health effects. Next, animal testing data of acute exposure has shown that some BDE congeners
may affect the immune system and cause skin irritation if the animal’s skin is lacerated (ATSDR,
2017). Furthermore, Darnerud et al. conducted studies pertaining to the clinical signs of toxicity
after acute exposure. After rats were exposed to high doses of PBDEs, investigators reported the
following clinical signs: diarrhea, red staining around the eyes and nose, reduced activity,
continuous chewing, piloerection and clonic persistent tremors of forelimbs (Darnerud et al.,
2001).

In humans, the only available data concerning acute PBDE health effects are from studies
of decaBDE. In one skin sensitization study, involving 200 volunteers (120 females and 80 males)
exposed to two decaBDE batches of unknown purity, no evidence of skin sensitization was
observed. These participants were treated with nine induction patches every two days. For every
treatment day, the test substance remained in contact with the participants’ skin for 24 hours.
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Neither of the two undisclosed decaBDE batches had an effect on skin sensitization. In another
study, the skin sensitization of a decaBDE mixture (decaBDE: 77.4%; nonaBDE: 21.8%; and,
octaBDE: 0.8%) was assessed for 50 volunteers. A five percent suspension of decaBDE in
petrolatum was spread over the participants’ skin three times per week for a period of three weeks.
Investigators did not find any skin sensitization among the participants (ATSDR, 2017). Finally,
a study of workers involved in the manufacture of polybrominated biphenyls and polybrominated
diphenyl ethers was conducted to investigate the acute health effects of PBDEs, including
decaBDE. These workers were reported to have a higher prevalence of primary hypothyroidism
and substantial reductions in conducting velocities in sensory and motor neurons than normal, after
being acutely exposed to PBDEs at the workplace. However, no other dermatologic or neurologic
changes were found (Darnerud et al., 2001).

2.6.2 Chronic
Similar to acute health effects, the chronic health effects of PBDEs are poorly understood
and requires a significant amount of research. Most of the known chronic health effects of PBDEs
are from animal studies. It is speculated that a long-term exposure to PBDEs has a higher chance
of causing health effects in comparison to short-term low levels of exposure. This is partly due to
the bioaccumulative property of PBDEs which occur over many years of exposure. Once again, in
relation to chronic health effects, decaBDEs are expected to be generally less toxic than lesserbrominated counterparts. Of major importance to possible chronic health effects is the potential to
cause cancer. Currently, it is unknown whether PBDEs can cause cancer in humans (ATSDR,
2017; USEPA, 2014).
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Although, rats and mice that ingested PBDEs throughout their lives developed liver tumors.
Overall, investigators have found a statistically significant increase in the incidence of carcinomas
in the livers of male rats exposed to low and high doses, and of female rats exposed to high doses.
Secondly, a significant increase in cases of hepatocellular adenoma or carcinoma was found in
male mice after low dose exposure (National Toxicology Program, 2006). Next, a significantly
increased incidence of follicular cell hyperplasia was found in male mice after being exposed to
high and low doses of decaBDE. The latter is thought to be a precursor to thyroid tumors in mice.
It is based on this relatively limited body of evidence that the EPA postulates that decaBDE may
possibly be carcinogenic to humans (ATSDR, 2017; USEPA, 2014). On the other hand, the EPA
describes lower-brominated congeners as not classifiable as human carcinogens (USEPA, 2014).

In case-control epidemiologic cancer studies, pancreatic cancer was not significantly
increased with increased levels of lipid lower-brominated PBDEs. Next, in a study of women from
California, of which were 78 cases and 56 controls, no significant association was found between
adipose tissue concentrations of lower-brominated PBDEs and breast cancer. Third, a study of
Alaskan women found no clear association between BDE-47 and breast cancer. In addition, blood
concentrations of lower-brominated PBDEs were not significantly associated with thyroid cancer
among participants from a large multicenter clinical trial in the U.S., which included 104 cases
and 208 controls. Furthermore, in a study of Swedish men and women with 19 cases and 27
controls, BDE-47 exposure was not significantly associated with non-Hodgkin’s lymphoma. Thus,
from the relatively brief amount of human studies of cancer risks in relation to lower-brominated
PBDE exposures, results have consistently shown that humans are not at significant risks to various
forms of cancer (ATSDR, 2017).
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2.6.3 Toxicokinetics
In general, toxicokinetic studies of PBDEs have indicated that the absorption, metabolism
and elimination of polybrominated diphenyl ethers are all dependent upon the congener, species
and gender. Also, animal studies have shown that pups have a higher body burden of PBDEs than
adults. This is because while a significant amount of PBDEs are transferred from mothers to pups
through breast feeding, the pups have a lesser capacity for PBDE elimination. Just as in animal
studies, children have been shown to carry a higher body burden of PBDEs in comparison to their
parents (Costa & Giordano, 2007). In humans, when comparing the amount of absorbed
polybrominated diphenyl ethers, with polychlorinated dibenzodioxins, polychlorinated dibenzo
furans and co-planar polychlorinated biphenyls from 1973 to 2000, human PBDE levels have
increased significantly while these other toxicants have all significantly decreased. The three most
common congeners in humans have been BDE-47, followed by BDE-153, then BDE-99 (Costa &
Giordano, 2007).

2.6.3.1 Absorption
In general, lesser-brominated congeners are more likely to enter the human body through
the lungs and stomach, and pass into the bloodstream than decaBDE. Also, during pregnancy,
PBDEs have been shown to enter the bodies of unborn babies through the placenta. Oral absorption
estimates are available for PBDEs and include the following. After forced administration of
PBDEs in lipophilic vesicles, the most recent estimates, show a range of 70-75% for BDE-47,
BDE-99, BDE-100, BDE-153, and BDE-154. An estimated range of 10-26% is expected for BDE-
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209 (deca-BDE). The mechanisms of oral absorption, including active transport and protein
binding, have not been determined (ATSDR, 2017).

To assess the bioavailability of PBDEs, studies of in vitro gastrointestinal models have
been conducted. Yu et al. found that the most important factor impacting PBDE bioaccessibility
was dietary fat; likely due to the lipophilicity of PBDEs. Further study of the bioaccessibility of
lesser-brominated BDE congeners in flour, rice, meat, fish and vegetables yielded a range of 2.6
to 41.3% in foodstuffs. Bioavailability of PBDEs in food increased as fat, and carbohydrate content
increased. On the other hand, bioavailability of PBDEs in food decreased with increasing protein
and fiber content (Yu et al., 2009).

The bioavailability of PBDEs have also been investigated in dust; the largest source of
PBDE exposure. Research by Lepom et al. found that the bioavailability of PBDEs found in
ingested dust was approximately less than 50%. From this investigation, researchers also reported
a bioavailability of 27 to 42% for lesser-brominated BDEs and approximately 10% for BDE-209
(Lepom et al., 2010). Similar results were found by Abdallah et al. Once again, the bioavailability
of BDE-209 (14%) was much lower than that for lesser-brominated BDE congeners (32 to 58%)
(Abdallah et al., 2012).

A few in vitro studies have been performed to investigate the diffusion potential of PBDEs
across dermal barriers for rats, mice, and human. According to Staskal et al., female mice that were
exposed to a dermal dose of 1 mg/kg
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C BDE-47 had a dermal absorption efficiency of 62%

(Staskal et al., 2005). Roper et al. reported that mean absorption efficiencies for 14C BDE-47 was
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14.58% in rat skin and 1.88% for human skin (Roper et al., 2006). Finally, Hughes et al. report a
mean absorption efficiency range of just 0.07-0.34% from the 14C decaBDE dose applied to mouse
skin in vitro (Hughes et al., 2001).

2.6.3.2 Distribution
As previously mentioned, research has shown that infants have a higher body burden of
PBDEs than their parents. One of the main reasons for the latter is due to PBDE absorption via
breastmilk. However, research has also demonstrated that PBDEs are also distributed to the
developing fetus from pregnant mothers via cord serum samples of non-occupationally exposed
mothers (Li et al., 2013). The majority of congeners found in maternal, cord sera and breast milk
samples have been tetraBDEs and pentaBDEs. Although, mounting evidence has shown the
presence of hexaBDEs, octaBDEs and decaBDEs in cord sera and mothers’ breast milk (ATSDR,
2017).

The distribution of PBDEs in animal and human tissues has also been investigated. In one
study, animals that were exposed to
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C-labeled BDE-47, BDE-99, BDE-100, BDE-153, BDE-

154, and BDE-209 (decaBDE) has shown that lower-brominated BDEs are distributed differently
than decaBDE. Specifically, investigators found that after absorption and an initial wide
distribution, lower-brominated congeners tended to accumulate more in adipose tissue. On the
other hand, decaBDE tended not to be distributed in adipose tissue. Instead, decaBDE appeared to
prefer highly perfused tissues, such as renal tissue, which are human tissues that circulate bodily
fluids (ATSDR, 2017).
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2.6.3.3 Metabolism
The primary metabolic pathway of PBDEs in humans and animals is oxidative
hydroxylation and follows the following series of steps. Polybrominated diphenyl ethers are
metabolized with phase I and phase II enzymes, forming hydroxylated PBDEs. Through this
metabolic pathway, monohydroxylated OH-PBDEs are formed. Hydroxylated PBDEs have been
found in samples of human blood and breast milk. These have also been found in the feces of
rodents that were exposed to 14C-labeled tetraBDEs, pentaBDEs, hexaBDEs and decaBDEs. The
process of PBDE oxidative hydroxylation has been validated in studies of in vitro metabolic
systems with primary hepatocytes or liver chromosomes in humans and rats (Cheng et al., 2008;
Erratico et al., 2011; Erratico et al., 2012; Erratico et al., 2013). Other metabolic fate processes for
PBDEs in mammals include the metabolic cleavage of the ether bond leading to a formation of
brominated phenols and the debromination of lesser-brominated PBDEs (Cheng et al., 2008;
Erratico et al., 2012; Erratico et al., 2013). Data from in vivo toxicokinetic studies of rodents
exposed to PBDEs have been deemed adequate by the ATSDR to propose the likely involvement
of cytochrome P450s in the formation of hydroxylated metabolites and hydroxylated debrominated
metabolites. Furthermore, in vitro studies of human liver microsomes or hepatocytes and human
recombinant CYP enzymes have shown that through hydroxylation and cleavage of the ether bond,
CYP2B6-mediated metabolism of BDE-47, 99 and 100 generated several metabolites, as
illustrated in Figures 2-4 respectively (Erratico et al., 2012; Erratico et al., 2013). Research of
human liver microsomes or hepatocytes has not shown a production of hydroxylated metabolites
of BDE-153 and BDE-209 (Lupton et al., 2009). Finally, it is interesting to note that there are
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naturally occurring OH-BDEs and brominated phenols known to be produced by sponges and
algae in marine environments (ATSDR, 2017).

Figure 2. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-47
Produced by Human Liver Microsomes (Erratico et al., 2013).
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Figure 3. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-99
Produced by Human Liver Microsomes (Erratico et al., 2012).
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Figure 4. Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE-99
Produced by Human Liver Microsomes (ATSDR, 2017).

2.6.3.4 Elimination
Just as in the case of absorption, the elimination of PBDEs depends on the chemical
structure of the BDE congener. In general, these flame retardants and their metabolites are
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eliminated from the body mainly through feces. A relatively very small amount is eliminated in
urine. DecaBDEs and their lower-brominated counterparts are all known to concentrate in human
breast milk. Thus, breastfeeding may serve as an additional source of elimination for nursing
mothers (Hooper et al., 2007; Jakobsson et al., 2012; Thomsen et al., 2010). The two general
classes of congeners also differ in their half-lives within the human body. The half-life for lowerbrominated BDE congeners is approximately 94 days. For decaBDEs, the approximate half-life is
significantly less at 15 days. Thus, lower-brominated PBDEs have a much longer residence time
in the body (ATSDR, 2017).

2.6.4 Mechanisms of Toxicity
Following exposure to PBDEs, the primary systems of concern in humans include the
following: the liver, nervous, male reproductive, developing and mature endocrine systems.
Although, the female reproductive, adult nervous system and the developing and mature immune
systems are also of concern, the evidence that is available for these endpoints is incomplete. Many
studies have been conducted to elucidate the likely mechanisms of toxicity for PBDEs. General
mechanisms of toxicity, such as Aryl hydrocarbon receptor (AhR)-mediated effects and hepatic
enzyme induction, and target-specific mechanisms have been investigated. Most mechanistic
studies, for specific targets, have been focused on neurological effects and endocrine disruption.
PBDEs share similar toxicological properties as PCBs likely due to their two-dimensional
structural similarities. However, PBDEs are more coplanar in nature due to the ether bridge. This
reduces the AhR binding affinity when compared to similar compounds. As a result, PBDEs are
less sensitive to the influence of ortho substitutions that inhibit the AhR binding capability of PCBs
(ATSDR, 2017; ATSDR, 2002). These attributes have implications on the nondioxin-like and
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dioxin-like effects of PBDEs, which are mediated by the AhR pathway. Studies of the structureactivity of PBDEs have demonstrated that although some BDE congeners are able to bind to AhR,
the binding affinities and induction of AhR-mediated responses are extremely weak or
insignificant; especially for commercial PBDE mixtures (ATSDR, 2017). Finally, Dingemans et
al. have reported that the toxicity of PBDEs should be investigated in conjunction with structurally
similar compounds such as nondioxin-like polychlorinated biphenyls because there is evidence
showing an additive effect when these two types of compounds are combined (Dingemans et al.,
2016). Meng et al. also reported synergistic effects between polybrominated diphenyl ethers,
polychlorinated biphenyls and organochlorine pesticides in a study of the association between
asthma and persistent organic pollutants among children in Shanghai, China (Meng et al., 2016).

2.6.5 Toxicity Assessment
The assessment of polybrominated diphenyl ethers will be limited to select outcomes. This
assessment concerns the most important public health risks, in addition to obesity; the primary
health outcome concerning this dissertation research. Moreover, epidemiological studies will be
presented, if available.

2.6.5.1 Developmental Effects
First, the neurodevelopment system is a target of concern in children for all PBDEs.
According to various human studies, results suggest that PBDEs influence the neurodevelopment
of children. In one cohort study, investigators found associations between maternal serum PBDE
concentrations and decreased IQ, hyperactivity at age 5 and executive functions (mental control
and self-regulation) deficits in those children from 5 to 8 years old (Braun et al., 2014; Chen et al.,
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2014; Donauer et al., 2015; Vuong et al., 2016). Other studies have reported a correlation between
cord serum PBDE concentrations in breast milk and adaptive behavior deficits in infants, mental
and physical developmental deficits in toddlers, social development and language deficits in
children (24 months old), increased impulsivity in toddlers, and attention deficit hyperactivity
disorder at age 4. Secondly, despite the inconsistency of developmental endocrine system effect
research, epidemiological data suggest that PBDEs can interact with the homeostasis of thyroid
hormones in infants and children. Human research showed inconsistencies in the investigation of
infant serum or cord blood thyroxine levels and PBDE developmental exposure. Results have also
been inconsistent when researchers investigated infant serum or cord blood triiodothyronine levels
and thyroid stimulating hormone in association with PBDE developmental exposure. In numerous
studies of animals, results have shown a reduction in serum triiodothyronine and thyroxine levels
in pups after receiving doses of pentaBDE or tetraBDE as low as 452 mg/kg/day in mice and 0.3
mg/kg/day in rats throughout gestation and lactation. Third, sufficient animal and limited human
data has shown that oral exposure to PBDEs during development may potentially affect the male
reproductive system (ATSDR, 2017). One study found, no relationships between maternal PBDE
levels and hypospadias in boys, adipose tissue concentrations of PBDEs in children and
cryptorchidism, or any measures of sexual maturation in girls (Carmichael et al., 2010). Yet, an
American longitudinal cohort study found a significant association between blood levels of PBDEs
for 6 to 8-year-old girls and delayed onset of puberty. However, more research is needed to
determine if PBDE levels in infants and children can cause altered reproductive effects in
adulthood. Last, limited animal and human data have shown that exposure to PBDEs may be able
to cause low birth weight among other endpoints of human physical development. However, such
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conclusions are relatively inconsistent (Costa & Giordano, 2007; Kuriyama et al., 2005; Lilienthal
et al., 2006; Toms et al., 2009a,b; Viberg et al., 2003).

2.6.5.2 Endocrine Effects
Several epidemiologic studies have investigated possible endocrine system effects of
PBDE exposure. First, many human studies have shown that PBDEs can disturb the endocrine
system and hormone levels. In one study conducted by Hooper et al., 4 production workers out of
a sample of 35 who worked at a decaBDE manufacturing plant presented with hypothyroidism
(Hooper & McDonald, 2000). However, specific findings in human studies have been very
inconsistent. Some studies have reported positive associations between thyroxine and PBDEs
while others have reported negative or no associations (ATSDR, 2017). Similar inconsistencies
exist for research concerning the association of thyroid stimulating hormone or triiodothyronine
with PBDE concentration. Although, there is sufficient data supporting the ability for PBDEs to
interact with the homeostasis of the thyroid hormone. Overall, current data from human and animal
studies suggests that the thyroid is likely a target of concern for humans (Costa & Giordano, 2007;
Hamers et al., 2006; Hooper & McDonald, 2000; Kim et al., 2012; Kovarich et al., 2011; Li et al.,
2013; Lilienthal et al., 2006; Norrgran et al., 2017).

Finally, the pancreatic effects of PBDEs have been studied in humans and animals.
Epidemiologic studies have been inconclusive. However, animal studies have shown that the
pancreas may be a target of concern after an oral dose of PBDE is provided. For example, a study
of male rats that were exposed to approximately 20 mg/kg/day to PBDEs in food for 70 days
showed a reduction in serum glucose levels. However, it should be noted that the study did not
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report the lowest dose at which point glucose levels were significantly lower in male rats. Another
study, investigated insulin regulation and pancreatic morphology in male rats after being exposed
to 0, 0.05, 1, or 20 mg/kg/day of decaBDE every day for a period of 8 weeks. Investigators reported
that the rats exposed to 1 and 20 mg/kg/day had a significant 50-60% decrease of serum insulin.
In addition, rats that were exposed to 0.05, 1 and 20 mg/kg/day had a significant increase of glucose
levels by 12, 18, and 21%, respectively (ATSDR, 2017; Ernest et al., 2012).

2.6.5.3 Hepatic Effects
Currently, the potential human hepatotoxic effects of PBDEs is based primarily on animal
data. There are no known animal studies of liver toxicity resulting from chronic lower-brominated
PBDE exposure. Also, for decaBDEs, hepatotoxic effect research have been relatively
inconsistent. Based on animal studies, acute exposure to lower-brominated BDE exposure is
potentially toxic to the human liver. Furthermore, pups appear to be more susceptible to liver
damage after decaBDE exposure, when compared to adult animals. Research has shown an
increase in liver weights and diffuse liver cell hypertrophy with increased cytoplasmic eosinophilia
in female rat pups that were exposed to ≥2 mg/kg/day and male rat pups exposed to 146 mg/kg/day
of decaBDE. Research has also shown that fatty degeneration and elevated liver enzymes can occur
in male rats after receiving a decaBDE dose that is ≥300 mg/kg/day (ATSDR, 2017).

2.6.5.4 Body Mass Index
A primary focus of this dissertation research is an investigation of the potential association
of PBDEs and obesity. Studies in this area of research has been relatively limited and inconclusive.
However, the following are some epidemiologic findings concerning the association of body mass
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index (BMI) with PBDE levels. The Centers for Disease Control & Prevention defines obesity as
having a BMI that is greater than 30. BMI is a calculation of an individual’s weight in kilograms
divided by the square of height in centimeters. In general, research shows that there is a moderate
correlation between BMI and body fat (Centers for Disease Control & Prevention [CDC], 2015).
This is important to remember due to the lipophilicity of PBDEs and their propensity to accumulate
in the human body (Hooper & McDonald, 2000). First, in a study of Taiwanese mothers,
investigators reported that children had low birth weight and height, and a decrease in Quetelet’s
BMI, after a daily intake of 20.6 ng/kg/day via breastmilk (Costa & Giordano, 2007). This dose is
lower than the average levels of PBDEs found in American human breast milk (approximately 306
ng/kg/day) but higher than levels reported in the general Taiwan population in 2001 (Costa &
Giordano, 2007). Other studies have reported no associations between PBDE exposure and the
latter physical health endpoints in children. Next, a follow-up study of the Center for the Health
Assessment of Mothers and Children of Salinas cohort was conducted to investigate the association
between blood levels of BDE-47, 99, 100, and 153 with measures of obesity like obesity and
overweight status, BMI and waist circumference. This investigation was conducted for 224 parents
and 216 children from 2-7 years old. Investigators found no association between PBDE levels and
measures of obesity. Although, once investigators adjusted for gender, significant effect
modification was observed. Thus, investigators conducted the analyses separately, for each gender,
and found a significant positive relationship between BMI z-score in 3.5-year-old boys and a 10fold rise in PBDE levels. This suggests that PBDEs have potential obesogenic effects for in-utero
exposure in male boys (ATSDR, 2017). On the other hand, a significant negative association was
observed in 3.5-year-old girls. Interestingly, Vuong et al. have reported no significant association
between PBDE levels in maternal blood, during the 16th week of pregnancy (geometric mean of
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39.1 ng/g lipid), and weight or height of children from 1 to 8 years old. However, Vuong and
colleagues found a negative association between BDE-153 and body mass index for children who
were 2 to 8 years old. A lower percent of body fat was also found for 8-year-old children (Vuong
et al., 2016). Finally, Agay-Shay et al. also found no significant associations between BMI z-scores
or risk of being overweight in children and maternal PBDE colostrum levels. It should be noted
that Agay-Shay et al. did not separate their analyses by sex as was done in the abovementioned
Salinas cohort study (Agay-Shay et al., 2015).
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Chapter 3
Methods
3.1 Data Source
The data analyzed for this research was generated from the 2003-2004 National Health and
Nutritional Survey (NHANES). NHANES is a major data collection program of the National
Center for Health Statistics (NCHS), which is a part of the Centers for Disease Control and
Prevention (CDC). The primary goal of NCHS is to generate vital and health statistics for the
country. Thus, the primary function of NHANES is to evaluate the health and nutritional status of
American children and adults. In order to generate statistical data on the amount, type, and
distribution of illnesses and disabilities within the United States, the National Health Monitoring
Act of 1956 was created (CDC, 2012).

The NHANES program was officially operational in the early 1960s. Since then, it has
conducted various surveys focused on different demographic groups and health topics. Prior to
1999, NHANES had been conducted periodically for periods of 2-4 years. However, there would
be periods of 1-5 years where health data were not being collected. Since 1999, the NHANES
program, now known as Continuous NHANES, has collected health and nutritional data on a
yearly basis to address emerging health concerns (CDC, 2012; Donauer et al., 2015).

The NHANES program surveys a representative sample of the American population every
year, amounting to approximately 5,000 people. These survey participants inhabit 15 counties
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throughout the country, which NHANES visit on a yearly basis. NHANES intentionally
oversamples minority populations (e.g., African Americans, and Hispanics) and the elderly (60
years or older) to produce reliable statistics. As it relates to the elderly, NCHS is currently
attempting to increase the knowledge concerning their health status. NHANES is a primary vehicle
for this target. While all participants visit the physician, in general, the older the person the more
extensive the examination tends to be. As it relates to minorities, oversampling is conducted
because minority groups tend to have drastically different health status and characteristics in
comparison to non-minorities (CDC, 2012; Donauer et al., 2015).

The current annual NHANES randomly selects approximately 7,000 American residents
who have an opportunity to participate in the survey. It is also important to note that their
participation is voluntary and confidential. Participants that are selected for the survey receive a
standardized physical examination along with a personal interview. The health interviews are
conducted in the homes of survey participants. The health examinations, on the other hand, are
conducted in fully-equipped and specially-designed mobile examination centers (MECs) that
travel across the nation during the survey period. These MECs are staffed with dietary and health
interviewers, physicians, medical and health technicians. Many of the staff members are
multilingual; especially in English and Spanish. In addition, the MECs uses a state-of-the-art
computers system using high-end servers which efficiently processes the NHANES data while
eliminating the use of manual coding or paper forms of data collection and reducing the potential
for coding errors. When necessary, participants are provided vehicle transportation to and from the
MECs. Surveyed individuals are provided a detailed summary of medical findings and are
compensated for their participation (CDC, 2012; Donauer et al., 2015).
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The collected data is published publically on the NHANES website and include the
following subsets: Demographics, Dietary, Examination, Laboratory, Questionnaire, and Limited
Access (NHANES, 2005a,b; NHANES, 2007; NHANES, 2008a,b). Demographics, Examination
and Laboratory subsets were used for this dissertation research. From the Demographics subset,
the Demographic Variables & Sample Weights XPT extension file was downloaded to include
age, gender and ethnicity in the analytical models. From the Examination subset, the Body
Measures XPT extension file was downloaded to include height (cm), weight (kg) and body mass
index (BMI). From the Laboratory subset, the Brominated Flame Retardants XPT extension file
was downloaded to include all the polybrominated diphenyl ether concentrations found in the
blood serum of study participants. Also from the laboratory subset, the Cholesterol – Low Density
Lipoprotein (LDL) & Triglycerides XPT was downloaded to include the LDL cholesterol and
triglycerides. This process was repeated for comparative analyses of phthalates using the
Phthalates – Urine XPT file, and Dioxin-Like PCBs using the Dioxins, Furans, & Coplanar PCBs
XPT file. Each of the XPT extension files are attached with a word document which provide a
description of the measured variable, limit of detection when necessary, sample requirements,
sampling protocols and procedures, and other important information pertaining to the data.

3.2 Sampling
3.2.1 PBDE Sampling
Participants that were eligible for this research were 12 years or older; age-capped at 85
years old. This includes a total of 2337 individuals. For confidentiality and for cross-analyses of
data, every individual was assigned a unique survey participant identifier (SEQN). Their PBDE
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concentrations were determined from an extraction of blood serum and/or plasma from each
participant. These specimens were collected in vials and stored under the appropriate frozen
temperature of -20 °C as elicited in the NHANES Laboratory/Medical Technologists Procedures
Manual (LPM). Once specimens were collected, they were processed and shipped to the Division
of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers
for Disease Control and Prevention for examination (CDC, 2012; NHANES, 2007).

The concentration of PBDEs are measured after sample cleanup and by using solid-phase
extraction. First, samples are pretreated using a Gilson 215 liquid handler. This process involves
the automated addition of internal standards, formic acid (denaturant) and water (diluent) and
mixing in-between each addition by rotation. The use of formic acid allows for the extraction of
the PBDEs from the samples. Next, during the extraction step, the analytes of interest of transferred
from an aqueous medium to an organic solvent. Then, samples are cleaned up by removing coextracted lipids through elution of the extract, using 8 mL of hexane, through a column of silica
(0.1g) and 1 g of silica/sulfuric acid (33% by weight). PBDE samples are cleaned and extracted
using an automated solid phase extraction workstation (Rapid Trace®, Caliper Life Sciences). In
addition, samples are evaporated by controlling vacuum, temperature and vortex action using
RapidVap® (LabConco) and transferred into gas chromatography vials for analysis (NHANES,
2007).

Isotope dilution gas chromatography high-resolution mass spectrometry (GC/IDHRMS) is
used to determine the final concentration of PBDE congeners. GC/IDHRMS allows for the
reduction or elimination of many interferences typically associated with low-resolution
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measurement of organohalogen compounds. Serum concentrations are reported in a lipid weight
basis (ng/g lipid) which is preferable due to PBDEs affinity for lipids and, thus, are distributed
within the body according to the distribution of the tissues lipid content (NHANES, 2007).

3.2.2 DL-PCB Sampling
Participants that were eligible for this research were 12 years or older; age-capped at 85
years old. This includes a total of 1723 individuals. For confidentiality and for cross-analyses of
data, every individual was assigned a unique survey participant identifier (SEQN). Their dl-PCB
concentration was determined from an extraction of blood serum and/or plasma from each
participant. These specimens were collected in vials and stored under the appropriate frozen
temperature of -20 °C as elicited in the NHANES Laboratory/Medical Technologists Procedures
Manual (LPM). Once specimens were collected, they were processed and shipped to the Division
of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers
for Disease Control and Prevention for examination (CDC, 2012; NHANES, 2008a).

Nine dL-PCBs were measured in serum using high resolution gas chromatography/isotopedilution high-resolution mass spectroscopy (HRGC/ID-HRMS) and include the following: PCB
105, PCB 118, PCB 156, PCB 157, PCB 167, PCB 189, PCB 126, PCB 81, PCB 169. 5 to 10 mL
serum specimens to be analyzed for dl-PCBs were spiked with
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C-labeled (13C12) internal

standards. Then, the analytes of interest were isolated in hexane using the C18 solid phase
extraction which was followed by a Power-Prep/6 (Fluid Management Systems) automated
cleanup and enrichment procedure using acidic, basic, and neutral multilayered silica gel and
alumina columns coupled to an AX-21 carbon column. From carbon to toluene, Dl-PCBs are

43

isolated in the reverse direction. After sample cleanup, a Turbovap II (Caliper Life Sciences) was
used to evaporate excess solvent to 350 µL. The remaining solvent was transferred to silanized
auto sampling vials which contained 1 µL of dodecane “keeper” and was allowed to go to
“dryness”. Each vial was reconstituted with 5 µL 13C12-labeled external standard before
quantification. Then, sample extracts were analyzed for dl-PCBs by HRGC/ID-HRMS. Using a
GC Pal (Leap Technology) auto sampler, 2µL were injected into an Agilent Technologies 6890
Gas Chromatograph operated in the splitless injection mode with a flow of 1 mL/minute helium
through a DB-5ms capillary column (30 m × 0.25 mm × 0.25 µm film thickness) where analytes
are separated prior to entering a Thermo Finnigan MAT95 XP (5 kV) magnetic sector mass
spectrometer operated in EI mode at 40 eV, using selected ion monitoring (SIM) at 10,000
resolving power (10% valley) (NHANES, 2008a).

In order to calibrate the mass spectrometer response factor v. concentration, calibration
standards containing known concentrations of each native (12C12) compound and its
corresponding 13C12 internal standard were used. Through interpolation from individual linear
calibration curves the concentration of each analyte was derived and adjusted for sample weight.
A variety of established criteria to evaluate the validity of all mass spectrometry data including:
signal-to-noise ratio ≥ 3 for the smallest native ion mass, relative retention time ratio of native to
isotopically labeled analyte within 3 parts per thousand compared to a standard, chromatographic
isomer specificity index with 95% limits, instrument resolving power ≥ 10,000, response ratios of
the two 12C12 and 13C12 ions within ± 20 % of their theoretical values and analyte recovery≥10 %
and ≤ 120%. The method detection limit was calculated by correcting for sample weight and
recovery, for each analyte. A summation method was used to estimate total lipid content of each
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specimen from its total cholesterol and triglycerides values. Serum concentrations are reported in
ng/g lipids (NHANES, 2008a).

3.2.3 Phthalate Sampling
In order to compare results with those of PBDE analyses, participants from 6 to 11 years
old were removed from the data set. Participants that were eligible for this research were 12 years
or older; age-capped at 85 years old. This includes a total of 2263 individuals. For confidentiality
and for cross-analyses of data, every individual was assigned a unique survey participant identifier
(SEQN). Phthalate concentration was determined from urine samples from each participant. These
specimens were collected in vials and stored under the appropriate frozen temperature of -20 °C
as elicited in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM). Once
specimens were collected, they were processed and shipped to the Division of Environmental
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease
Control and Prevention for examination (CDC, 2012; NHANES, 2008b).

High

performance

liquid

chromatography-electrospray

ionization-tandem

mass

spectrometry (HPLC-ESI-MS/MS) was used for the quantitative detection of the following
phthalate metabolites in urine: mono(2-ethyl-5-carboxypentyl) phthalate (mECPP), mono(2-ethyl5-hydroxyhexyl)

phthalate

(mEHHP),

mono(2-ethyl-5-oxohexyl)

phthalate

(mEOHP),

monoisononyl phthalate (mNP), monobenzyl phthalate (mBzP), monooctyl phthalate (mOP),
mono (2-ethylhexyl) phthalate (mEHP), monocyclohexyl phthalate (mCHP), mono (3carboxypropyl) phthalate (mCPP), mono-isobutyl phthalate (miBP), monobutyl phthalate (mBP),
monoethyl phthalate (mEP) and monomethyl phthalate (mMP). Urinary samples were processed
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using enzymatic deconjugation of the glucuronidated phthalate monoesters. This was followed by
on-line solid phase extraction along with reversed phase HPLC-ESI-MS/MS. The incorporation of
isotopically-labeled internal standards for each of the phthalate metabolites allowed the
improvement of assay precision. Also, 4-methyl umbelliferone glucuronide was used to track
deconjugation efficiency. Urinary concentrations are reported in ng/mL (NHANES, 2008b).

3.3 Data Analysis
Demographics, Examination and Laboratory XPT extension files were downloaded from
the 2003-2004 NHANES. These laboratory subsets were uploaded and merged into SAS statistical
software (Version 9.4) for preliminary analyses. Preliminary analyses included generating
frequency distributions for all demographic groups and analytes (e.g., PBDEs, dl-PCBs,
Phthalates). For PBDEs, analyses were performed on a sum of 10 congeners and two of the most
prevalent congeners, BDE-47 and BDE-99, representing 75% of PBDEs in commercial mixtures
(NHANES, 2007.). For dl-PCBs, analyses were performed on 9 congeners (NHANES, 2008a).
For Phthalates, analyses were performed on 13 phthalate metabolites (NHANES, 2008b).
Descriptive statistics such as the mean, minimum, maximum, standard deviation and standard error
were calculated for analyte concentrations given age, gender, and ethnicity. Microsoft Excel was
also used to generate graphs and tables for data visualization and supplementary analysis.

During preliminary analyses of the concentration of analytes, it was determined that 562
observations did not have a recorded concentration for dl-PCBs; and 434 were missing for
phthalates (NHANES, 2008b). These observations were removed from the analyses to reduce bias.
In addition, 297 observations had concentrations which were below the limit of detection (LOD)
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for PBDEs. The LOD of every BDE congener was identified from the NHANES Lab Manual for
PBDEs. Following industrial convention, the missing values were replaced by LOD/Square root
(2) (NHANES, 2007). There were other instances where the data of interest was missing.
Specifically, some individual data was missing for height in kg, weight in cm, BMI, triglycerides,
and LDL cholesterol. In these cases, the missing data were omitted to reduce the bias or
misinterpretation of analytical results.

To investigate the validity of the research hypotheses, the following analyses were
performed. Two major statistical procedures were utilized including analysis of variance
(ANOVA) and logistic regression, when appropriate. First, ANOVA was calculated for any
analysis that included dichotomous (or categorical) variables such as gender, age group or
ethnicity. ANOVA was used to determine whether the average concentrations of analytes were
significantly different among genders, age groups, ethnicities, and genders and ethnicities. A
significance level of 0.05 (95% confidence level) was used for all ANOVA analyses. In other
words, a resulting p-value less than 0.05 indicated a significant result.

In addition, a logistic regression was conducted for BMI, given quartiles of analyte
concentrations. Quartiles of analyte concentration were generated for statistical significance. It
should also be noted that the CDC generates BMI values for adults who are 20 years or older.
Thus, the data analysis of BMIs excluded participants who were under the age of 20. Based upon
guidelines set forth by the CDC, participants were categorized according to their BMI.
Specifically, participants were marked as underweight (BMI<18.5), normal or healthy weight
(BMI=18.5-24.9), overweight (BMI=25.0-29.9), or obese (BMI≥30) (CDC, 2015). The logistic
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regression analyses were used to calculate odds ratios (OR) which determined whether higher
concentrations of a given analyte led to a higher odd of being overweight or obese. These analyses
incorporated age (20 years or older), gender, ethnicity, LDL cholesterol, triglycerides and analytes
separated into quartiles. If the OR values are equal to 1, this signifies that there is no difference
between comparative groups in relation to an outcome of interest. If OR is above or less than 1
than one of the two measure groups has a greater or lesser odd, respectively, of achieving an
outcome in question. The further away from 1 the OR, the more drastic the difference between the
two comparative groups (e.g., males v. females). To account for precision of OR measurements,
95% Wald confidence limits are assigned for each calculation of OR point estimates. A point
estimate outside of that confidence interval is deemed significant.

Lastly, analyte concentrations among demographic categories were specifically compared
using a paired t-test in Microsoft Excel. For each analysis a 95% confidence interval was utilized,
where a calculated p-value less than 0.05 indicated a significant result. Correlation coefficients
were used to present the strength of association among analyte concentrations. In addition,
correlation of determinations were generated to measure the percent of variation that could be
explained by the regression equation.
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Chapter 4
Results
Results are ordered by analyte(s); that is, BDE-47, BDE-99, sum of PBDEs, dl-PCBs,
followed by phthalates. Analysis for each analyte(s) was conducted to determine the following:
•

Frequency distribution of analytes, demographic categories and demographic
categories per quartile.

•

Average concentration of analytes for all individuals in the sample and per
demographic category.

•

Comparison of means for all demographic categories using ANOVA.

•

Calculation of odds of being overweight and obese in association with analyte
concentration compared to other factors, using logistic regression.

•

Comparison of results using paired t-test.

•

Summary of results.

4.1 Overall Detection Frequency
Analytes were detected in at least 85% of samples. Samples detected include values that
were below the limit of detection, which were subsequently treated using LOD/Square root (2).
These values could not be separated from the graph since they were not enumerated for dl-PCBs.
The CDC automatically used the LOD/Square root (2) treatment for such analytes. Also, it
should be noted that for the sum of all PBDEs, missing values from individual congeners were
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automatically omitted in SAS and did not affect the final concentrations calculated for
participants.

Detection of Analytes Among Individuals

Number of Samples

3500
3000
2500
2000

434
321

0

352

1500
1000

2337

2016

1985

BDE-47

BDE-99

562

2285

2697

500
0
All PBDEs*

Samples Detected

All dl-PCBs All Phthalates

Samples Missing

Figure 5. Number of samples detected.
Table 2. Detections among individuals in the dataset.
BDE-47
Samples

BDE-99

All PBDEs* All dl-PCBs All
Phthalates
2337
2285
2697
0
562
434
100.00%
80.26%
86.14%

Detected
2016
1985
Missing
321
352
Percent
86.26% 84.94%
Detected
*Note: Although the sum of PBDEs contains some missing values, when calculating the sum
of concentrations SAS automatically ignores missing values.
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4.2 Polybrominated Diphenyl Ethers
4.2.1 BDE-47
4.2.1.1 Frequency Distributions

Frequency Distribution of BDE-47
Concentration Ranges Per Quartile
600

Frequency

500

584

584

584

585

Q1 (0-6.8)

Q2 (6.8-17.5)

Q3 (17.5-40.1)

Q4 (40.1-2350)

400
300
200
100
0

Quartiles & PBDE Concentration Ranges in PPB

Figure 6. Frequency distribution of BDE-47 per quartile range.
Table 3. Frequency distribution table of BDE-47 per quartile range.
BDE-47 (Quartiles)
Concentration Range
Q1 (0-6.8)
Q2 (6.8-17.5)
Q3 (17.5-40.1)
Q4 (40.1-2350)

Frequency
584
584
584
585

Percent Min
Max
24.99% 0.004384062 2350
24.99%
24.99%
25.03%
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Table 4. Frequency distribution table of age ranges cross-referenced with BDE-47 quartiles.
RIDAGEYR refers to age in years from the 2003-2004 NHANES Demographic dataset and
LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame Retardants
dataset.

Table 5. Frequency distribution table of gender cross-referenced with BDE-47 quartiles.
RIAGENDR refers to gender from the 2003-2004 NHANES Demographic dataset and
LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame Retardants
dataset.
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Table 6. Frequency distribution table of ethnicity cross-referenced with BDE-47 quartiles.
RIDRETH1 refers to CDC-defined ethnicity from the 2003-2004 NHANES Demographic
dataset and LBXBR3LA refers to BDE-47 from the 2003-2004 NHANES Brominated Flame
Retardants dataset.
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4.2.1.2 Comparative Statistics

Distribution of Average Blood BDE-47
Concentrations Among Age Groups in 2003-04
NHANES
Concentrations in ppb

60
56.32

50
40

40.07

43.08

40.41

44.28

30
20
10
0
12 to 18

19 to 30

31 to 50

51 to 84

85 and
Above

Age Group
Figure 7. Comparison of average BDE-47 concentrations among age groups, in years.
Difference in mean BDE-47 concentrations between age groups were insignificant; p-value
>0.05.
Table 7. Comparison of average BDE-47 concentrations among age groups, in years.
Age Group, in years
12 to 18 19 to 30 31 to 50 51 to 84 85 and Above
Concentrations, in ng/g lipids 40.068 43.083 40.411 44.275 56.318
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Concentrations in ppb

Average Blood BDE-47 Concentrations Based
on Gender in 2003-04 NHANES Survey
50
40
30
20
10
0

47.52
37.48

Male

Female
Gender

Figure 8. Comparison of average BDE-47 concentrations among genders. Difference in mean
BDE-47 concentrations between genders were significant; p-value <0.05.
Table 8. Comparison of average BDE-47 concentrations among genders.
Gender
Concentrations, in ng/g
lipids

Male
47.524

Female
37.476

Concentrations in ppb

Average Blood BDE-47 Concentrations Based on
Race/Ethnicity in 2003-04 NHANES Survey
50
40
30

42.46

39.82
31.34

20

46.68
37.15

10
0
Mexican
American

Other
Hispanic

Non-Hispanic Non-Hispanic Other Race White
Black
Including
Multi-Racial
Race/Ethnicity

Figure 9. Comparison of average BDE-47 concentrations among ethnic groups. Difference in
mean BDE-47 concentrations between ethnicities were insignificant; p-value >0.05.
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Table 9. Comparison of average BDE-47 concentrations among ethnic groups.
Ethnicity

Mexican
American

Other
Hispanic

Concentrations,
in ng/g lipids

39.819

31.341

NonHispanic
White
42.463

NonHispanic
Black
46.681

Other Race Including MultiRacial
37.145

Concentrations in PPB

Distribution of BDE-47 Concentrations Given Genders &
Ethnicities
55.072

60
50
40

42.751

46.760
37.614

43.671

38.504

37.030
25.711

30

38.545

32.485

20
10
0

Genders & Ethnicities

Figure 10. Comparison of average BDE-47 concentrations among gender and ethnicities.
Difference in average BDE-47 concentrations is insignificant, given genders & ethnicities; pvalue >0.05.
Table 10. Comparison of average BDE-47 concentrations among gender and ethnicities.
Ethnicity & Gender
Mexican_Male
OtherHispanic_Male
White_Male
Black_Male
OtherRace/Multiracial_Male

Concentrations,
in ng/g lipids
42.751
37.614
46.760
55.072
43.671
56

Table 10. (continued).
Ethnicity & Gender

Concentrations,
in ng/g lipids
OtherHispanic_Female
25.711
White_Female
38.504
Black_Female
38.545
OtherRace/Multiracial_Female 32.485

Concentrations in PPB

Distribution of BDE-47 Concentrations Given Males &
Ethnicities
55.072

60
50

42.751

40

46.760
37.614

43.671

30
20
10
0

Males & Ethnicities

Figure 11. Comparison of average BDE-47 concentrations among males and ethnicities.
Difference in average BDE-47 concentrations is insignificant, given males & ethnicities; p-value
>0.05.
Table 11. Comparison of average BDE-47 concentrations among males and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Male
42.751
OtherHispanic_Male
37.614
White_Male
46.760
Black_Male
55.072
OtherRace/Multiracial_Male 43.671
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Distribution of BDE-47 Concentrations Given Females
& Ethnicities
Concentrations in PPB

45
40

38.504

37.030

32.485

35
30

38.545

25.711

25
20
15
10
5
0

Females & Ethnicity

Figure 12. Comparison of average BDE-47 concentrations among females and ethnicities.
Difference in average BDE-47 concentrations is insignificant, given females & ethnicities; pvalue >0.05.
Table 12. Comparison of average BDE-47 concentrations among females and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Female
37.030
OtherHispanic_Female
25.711
White_Female
38.504
Black_Female
38.545
OtherRace/Multiracial_Female 32.485
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4.2.1.3 Logistic Regression Statistics

Odds of Being Overweight Based on Demographics & BDE-47
7

6

Odds Ratio

5
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2

1
0.717

0

1.009

Female v. Male Age in Years

1.292

1.288

0.627

0.782

High v. Low
Triglycerides

High v. Low
LDL

OtherRace &
Multiracial v.
Mexican
American

NonHispanic
Black v.
Mexican
American

0.980

1.841

1.465

1.007

1.072

NonHispanic Other Hispanic Quartile 4 v. 1 Quartile 3 v. 1 Quartile 2 v. 1
White v.
v. Mexican
Mexican
American
American

Effect

Figure 13. Odds of being overweight in relation to blood concentration of BDE-47. From a
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which
increases the odds of being overweight. Most interestingly is the 1.841 odds ratio produced for
Other Hispanic (non-Mexican) Vs. Mexican categories.
Table 13. Odds of being overweight in relation to blood concentration of BDE-47.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American

Odds
Ratio
0.717
1.009
1.292
1.288
0.627

95% Confidence
Intervals
0.517
0.995
1.000
1.017
0.852
1.959
0.784
2.116
0.249
1.576

0.782
0.980
1.841

0.465
0.644
0.703

1.317
1.491
4.824
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Table 13. (Continued).
Effect

Odds
Ratio
1.465
1.007
1.072

Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

95% Confidence
Intervals
0.898
2.389
0.611
1.661
0.673
1.707

Odds of Being Obese Based on Demographics & BDE-47
6

5

Odds Ratio

4

3

2

1
1.737

0

Female v.
Male

1.002

2.081

Age in Years High v. Low
Triglycerides

0.580

0.309

1.307

0.671

0.484

High v. Low OtherRace & NonHispanic NonHispanic
LDL
Multiracial v.
Black v.
White v.
Mexican
Mexican
Mexican
American
American
American

1.195

1.560

1.655

Other
Quartile 4 v. 1Quartile 3 v. 1Quartile 2 v. 1
Hispanic v.
Mexican
American

Effect

Figure 14. Odds of being obese in relation to blood concentration of BDE-47. No comparisons
yielded significant odds of obese BMI.
Table 14. Odds of being obese in relation to blood concentration of BDE-47.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American

Odds
Ratio
1.737
1.002
2.081
0.580
0.309

95% Confidence
Intervals
1.251
2.412
0.993
1.011
1.371
3.159
0.339
0.994
0.116
0.820

1.307

0.800

2.136
60

Table 14. (Continued).
Effect
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

Odds
Ratio
0.671
0.484
1.195
1.560
1.655

95% Confidence
Intervals
0.443
1.017
0.163
1.443
0.722
1.978
0.949
2.565
1.035
2.645

4.2.2 BDE-99
4.2.2.1 Frequency Distributions

Frequency Distribution of BDE-99
Concentration Ranges Per Quartile
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Figure 15. Frequency distribution of BDE-99 per quartile range.
Table 15. Frequency distribution table of BDE-99 per quartile range.
BDE-99 (Quartiles)
Concentration Range
Q1 (0-1.7)
Q2 (1.7-3.6)
Q3 (3.6-8.9)
Q4 (8.9-692)

Frequency
569
593
594
581

Percent
24.35%
25.37%
25.42%
24.86%

Min
Max
0.004949747 692
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Table 16. Frequency distribution table of age ranges cross-referenced with BDE-99 quartiles.
RIDADEYR refers to age in years from the 2003-2004 NHANES Demographic dataset and
LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame Retardants
dataset.

Table 17. Frequency distribution table of gender cross-referenced with BDE-99 quartiles.
RIAGENDR refers to gender from the 2003-2004 NHANES Demographic dataset and
LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame Retardants
dataset.
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Table 18. Frequency distribution table of ethnicity cross-referenced with BDE-99 quartiles.
RIDRETH1 refers to CDC-defined ethnicity from the 2003-2004 NHANES Demographic
dataset and LBXBR5LA refers to BDE-99 from the 2003-2004 NHANES Brominated Flame
Retardants dataset.
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4.2.2.2 Comparative Statistics

Concentrations in ppb

Distribution of Average Blood BDE-99
Concentrations Among Age Groups in 2003-04
NHANES
16
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14.81
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31 to 50

10.42

51 to 84
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Age Group
Figure 16. Comparison of average BDE-99 concentrations among age groups, in years.
Difference in mean BDE-99 concentrations between age groups were insignificant; p-value
>0.05.
Table 19. Comparison of average BDE-99 concentrations among age groups, in years.
Age Group, in years

12 to 18

19 to 30

31 to 50

51 to 84

Concentrations, in ng/g
lipids

10.058

11.795

11.873

10.421

85 and
Above
14.814
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Concentrations in ppb

Average Blood BDE-99 Concentrations Based
on Gender in 2003-04 NHANES Survey
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12.79
9.37

5
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Female
Gender

Figure 17. Comparison of average BDE-99 concentrations among genders. Difference in mean
BDE-99 concentrations between genders were significant; p-value <0.05.
Table 20. Comparison of average BDE-99 concentrations among genders.
Gender
Concentrations, in ng/g
lipids

Male
12.793

Female
9.365

Concentrations in ppb

Average Blood BDE-99 Concentrations Based on
Race/Ethnicity in 2003-04 NHANES Survey
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Black
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Race/Ethnicity

Figure 18. Comparison of average BDE-99 concentrations among ethnic groups. Difference in
mean BDE-99 concentrations between ethnicities were insignificant; p-value >0.05.
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Table 21. Comparison of average BDE-99 concentrations among ethnic groups.
Ethnicity

Mexican
American

Other
Hispanic

Concentrations,
in ng/g lipids

9.840

7.984

NonHispanic
White
11.025

NonHispanic
Black
12.776

Other Race Including MultiRacial
9.387

Average Concentrations in ppb

Distribution of BDE-99 Concentrations Given Genders &
Ethnicities
18
16
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12
10
8
6
4
2
0

15.451
11.252
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9.289
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8.497

9.697
6.814

10.181
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Genders & Ethnicities

Figure 19. Comparison of average BDE-99 concentrations among gender and ethnicities.
Difference in average BDE-99 concentrations is insignificant, given genders & ethnicities; pvalue >0.05.
Table 22. Comparison of average BDE-99 concentrations among gender and ethnicities.
Ethnicity & Gender
Mexican_Male
OtherHispanic_Male
White_Male
Black_Male
OtherRace/Multiracial_Male
Mexican_Female

Concentrations,
in ng/g lipids
11.252
9.289
12.466
15.451
11.221
8.497
66

Table 22. (Continued).
Ethnicity & Gender

Concentrations,
in ng/g lipids
White_Female
9.697
Black_Female
10.181
OtherRace/Multiracial_Female 8.077

Average Concentrations in ppb

Distribution of BDE-99 Concentrations Given Males &
Ethnicities
18
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Figure 20. Comparison of average BDE-99 concentrations among males and ethnicities.
Difference in average BDE-99 concentrations is insignificant, given males & ethnicities; p-value
>0.05.
Table 23. Comparison of average BDE-99 concentrations among males and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Male
11.252
OtherHispanic_Male
9.289
White_Male
12.466
Black_Male
15.451
OtherRace/Multiracial_Male 11.221
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Average Concentrations in ppb

Distribution of BDE-99 Concentrations Given Females &
Ethnicities
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Figure 21. Comparison of average BDE-99 concentrations among females and ethnicities.
Difference in average BDE-99 concentrations is insignificant, given females & ethnicities; pvalue >0.05.
Table 24. Comparison of average BDE-99 concentrations among females and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Female
8.497
OtherHispanic_Female
6.814
White_Female
9.697
Black_Female
10.181
OtherRace/Multiracial_Female 8.077
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4.2.2.3 Logistic Regression Statistics

Odds of Being Overweight Based on Demographics & BDE-99
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Figure 22. Odds of being overweight in relation to blood concentration of BDE-99. From a
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which
increases the odds of being overweight. Most interestingly is the 1.833 odds ratio produced for
Other Hispanic (non-Mexican) Vs. Mexican categories.
Table 25. Odds of being overweight in relation to blood concentration of BDE-99.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American

Odds
Ratio
0.715
1.008
1.308
1.322
0.607

95% Confidence
Intervals
0.515
0.992
0.999
1.017
0.859
1.992
0.799
2.188
0.241
1.528

0.777

0.461

1.308
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Table 25. (Continued).
Effect
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

Odds
Ratio
0.958
1.833
1.409
0.976
1.033

95% Confidence
Intervals
0.630
1.458
0.699
4.804
0.849
2.338
0.590
1.615
0.638
1.673

Odds of Being Obese Based on Demographics & BDE-99
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Figure 23. Odds of being obese in relation to blood concentration of BDE-99. No comparisons
yielded significant odds of obese BMI.
Table 26. Odds of being obese in relation to blood concentration of BDE-99.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL

Odds
Ratio
1.745
1.002
2.166
0.616

95% Confidence
Intervals
1.257
2.423
0.993
1.010
1.422
3.301
0.358
1.059
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Table 26. (Continued).
Effect
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

Odds
Ratio
0.308

95% Confidence
Intervals
0.116
0.817

1.265
0.652
0.476
1.002
1.156
1.285

0.775
0.430
0.160
0.598
0.701
0.796

2.065
0.987
1.415
1.677
1.904
2.075

4.2.3 Sum of PBDEs
4.2.3.1 Frequency Distributions

Frequency

Frequency Distribution of PBDE
Concentration Ranges Per
Quartile
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Figure 24. Frequency distribution of the sum of PBDEs per quartile range.
Table 27. Frequency distribution table of the sum of PBDEs per quartile range.
Sum of 10 PBDEs (Quartiles)
Concentration Range Frequency
Q1 (0-16.5)
585
Q2 (16.5-35.8)
583
Q3 (35.8-77.3)
584
Q4 (77.3-3676.2)
585

Percent Min
Max
25.03% 0.044901281 3676.204667
24.95%
24.99%
25.03%
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Table 28. Frequency distribution table of age ranges cross-referenced with total PBDE quartiles.
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Table 29. Frequency distribution table of gender cross-referenced with total PBDE quartiles.

Table 30. Frequency distribution table of ethnicity cross-referenced with total PBDE quartiles.
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4.2.3.2 Comparative Statistics

Concentrations in ppb

Distribution of Average Blood PBDE
Concentrations Among Age Groups in 2003-04
NHANES
120
100

104.90

80
60

76.13

81.09

78.43

84.65

12 to 18

19 to 30

31 to 50

51 to 84

40
20
0
85 and
Above

Age Group
Figure 25. Comparison of average PBDE concentrations among age groups, in years. Difference
in mean PBDE concentrations between age groups were insignificant; p-value >0.05.
Table 31. Comparison of average PBDE concentrations among age groups, in years.
Age Group, in years

12 to 18

19 to 30

31 to 50

51 to 84

Concentrations, in ng/g
lipids

76.134

81.089

78.433

84.654

85 and
Above
104.898
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Concentrations in ppb

Average Blood PBDE Concentrations Based on Gender
in 2003-04 NHANES Survey
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Figure 26. Comparison of average PBDE concentrations among genders. Difference in mean
PBDE concentrations between genders were significant; p-value <0.05.
Table 32. Comparison of average PBDE concentrations among genders.
Gender
Concentrations, in ng/g
lipids

Male
93.780

Female
68.599

Concentrations in ppb

Average Blood PBDE Concentrations Based on
Race/Ethnicity in 2003-04 NHANES Survey
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Figure 27. Comparison of average PBDE concentrations among ethnic groups. Difference in
mean PBDE concentrations between ethnicities were insignificant; p-value >0.05.
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Table 33. Comparison of average PBDE concentrations among ethnic groups.
Ethnicity

Mexican
American

Concentration 71.607
s, in ng/g lipids

Other
Hispanic

NonHispanic
White
85.321

59.555

NonHispanic
Black
86.671

Other Race Including
Multi-Racial
64.954

Distribution of PBDE Concentrations Given Genders &
Ethnicities
Concentrations in PPB

120
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80
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79.240
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Figure 28. Comparison of average PBDE concentrations among gender and ethnicities.
Difference in average PBDE concentrations is insignificant, given genders & ethnicities; p-value
>0.05.
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Table 34. Comparison of average PBDE concentrations among gender and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Male
79.240
OtherHispanic_Male
74.493
White_Male
97.469
Black_Male
105.795
OtherRace/Multiracial_Male
77.755
Mexican_Female
64.348
OtherHispanic_Female
46.148
White_Female
74.130
Black_Female
68.126
OtherRace/Multiracial_Female 55.810

Concentrations in PPB

Distribution of PBDE Concentrations Given
Males & Ethnicities
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Figure 29. Comparison of average PBDE concentrations among males and ethnicities.
Difference in average PBDE concentrations is insignificant, given males & ethnicities; p-value
>0.05.
Table 35. Comparison of average PBDE concentrations among males and ethnicities.
Ethnicity & Gender
Mexican_Male
OtherHispanic_Male

Concentrations,
in ng/g lipids
79.240
74.493
77

Table 35. (Continued).
Ethnicity & Gender

Concentrations,
in ng/g lipids
Black_Male
105.795
OtherRace/Multiracial_Male 77.755

Concentrations in PPB

Distribution of PBDE Concentrations Given Females &
Ethnicities
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Figure 30. Comparison of average PBDE concentrations among females and ethnicities.
Difference in average PBDE concentrations is insignificant, given females & ethnicities; p-value
>0.05.
Table 36. Comparison of average PBDE concentrations among females and ethnicities.
Ethnicity & Gender

Concentrations,
in ng/g lipids
Mexican_Female
64.348
OtherHispanic_Female
46.148
White_Female
74.130
Black_Female
68.126
OtherRace/Multiracial_Female 55.810
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4.2.3.3 Logistic Regression Statistics
Odds of Being Overweight Based on Demographics & All PBDEs
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0.728

0

Female v.
Male

1.008

1.310

Age in Years High v. Low
Triglycerides

1.312

0.615

0.759

0.945

High v. Low OtherRace & NonHispanic NonHispanic
LDL
Multiracial v.
Black v.
White v.
Mexican
Mexican
Mexican
American
American
American

1.871

1.482

0.821

1.054

Other
Quartile 4 v. 1Quartile 3 v. 1Quartile 2 v. 1
Hispanic v.
Mexican
American

Effect

Figure 31. Odds of being overweight in relation to blood concentration of PBDEs. From a
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables
and Overweight BMI as the outcome, Ethnicity is the only significant exposure variable which
increases the odds of being overweight. Most interestingly is the 1.871 odds ratio produced for
Other Hispanic (non-Mexican) Vs. Mexican categories.
Table 37. Odds of being overweight in relation to blood concentration of PBDEs.
Effect

Odds Ratio

Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1

0.728
1.008
1.310
1.312
0.615

95% Confidence
Intervals
0.525
1.011
0.999
1.017
0.863
1.987
0.798
2.157
0.244
1.549

0.759
0.945
1.871
1.482

0.450
0.621
0.711
0.929

1.280
1.438
4.925
2.363
79

Table 37. (Continued).
Effect

Odds Ratio

Quartile 3 v. 1
Quartile 2 v. 1

0.821
1.054

95% Confidence
Intervals
0.501
1.347
0.665
1.672

Odds of Being Obese Based on Demographics & All PBDEs
6
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Odds Ratio

4
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1

1.728

0
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Male

1.002
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0.668

Age in Years High v. Low High v. Low OtherRace & NonHispanic NonHispanic
Triglycerides
LDL
Multiracial v.
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Mexican
Mexican
Mexican
American
American
American

0.522
Other
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American
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1
1
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Figure 32. Odds of being obese in relation to blood concentration of PBDEs. No comparisons
yielded significant odds of obese BMI.
Table 38. Odds of being obese in relation to blood concentration of PBDEs.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1

Odds
Ratio
1.728
1.002
2.157
0.597
0.299

95% Confidence
Intervals
1.243
2.402
0.993
1.011
1.418
3.281
0.349
1.022
0.112
0.796

1.322
0.668
0.522
1.043

0.807
0.441
0.175
0.643

2.165
1.011
1.558
1.694
80

Table 38. (Continued).
Effect

Odds
Ratio
1.239
1.839

Quartile 3 v. 1
Quartile 2 v. 1

95% Confidence
Intervals
0.761
2.017
1.161
2.912

4.3 Dioxin-Like Polychlorinated Biphenyls
4.3.1 Frequency Distributions

Frequency Distribution of Dioxin-Like
PCB Concentration Ranges Per Quartile
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Figure 33. Frequency distribution of the sum of dl-PCBs per quartile range.
Table 39. Frequency distribution table of the sum of dl-PCBs per quartile range.
Sum of DL-PCBs (Quartiles)
Concentration Range
Frequency
Q1 (1.300-4.5976)
431
Q2 (4.5978 -9.414)
430
Q3 (9.432-22.315)
431
Q4 (22.405 -358.862)
431

Percent
25.01%
24.96%
25.01%
25.01%

Min
1.3001

Max
358.8613
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Table 40. Frequency distribution table of age ranges cross-referenced with total dl-PCB
quartiles.
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Table 41. Frequency distribution table of gender cross-referenced with total dl-PCB quartiles.

Table 42. Frequency distribution table of ethnicities cross-referenced with total dl-PCB
quartiles.
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4.3.2 Comparative Statistics

Distribution of Average Blood DL-PCB
Concentrations Among Age Groups in '03-'04
NHANES
Levels in ppb
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Figure 34. Comparison of average dl-PCB concentrations among age groups, in years.
Difference in mean DL-PCB concentrations between age groups were significant; p-value <0.05.
Table 43. Comparison of average dl-PCB concentrations among age groups, in years.
Age, in years

12 to 18

19 to 30

31 to 50

51 to 84

Concentrations, ng/g
lipids

5.652

6.578

15.025

39.665

85 and
Above
75.020

84

Average Blood DL-PCB Concentrations Based
on Gender in '03-'04 NHANES Survey
25

Levels in ppb

20

20.64
17.99

15
10
5
0

Male

Female
Gender

Figure 35. Comparison of average dl-PCB concentrations among genders. Difference in mean
DL-PCB concentrations between genders were insignificant; p-value >0.05.
Table 44. Comparison of average dl-PCB concentrations among genders.
Gender
Concentrations, ng/g
lipids

Male
17.987

Female
20.635

Levels in ppb

Average Blood DL-PCB Concentrations
Based on Race/Ethnicity in '03-'04
NHANES Survey
25
20
15
10
5
0

17.78

22.96

20.95

19.24

10.48
Mexican
American

Other Hispanic Non-Hispanic Non-Hispanic
White
Black

Other Race Including
Multi-Racial

Race/Ethnicity

Figure 36. Comparison of average dl-PCB concentrations among ethnic groups. Difference in
mean DL-PCB concentrations between races were significant; p-value <0.05. Non-Hispanic
White vs. Mexican American and Non-Hispanic Black vs. Mexican American PBDE
concentrations were the significant comparisons.
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Table 45. Comparison of average dl-PCB concentrations among ethnic groups.
Ethnicity

Mexican
American

Other
Hispanic

Concentrations,
ng/g lipids

10.477

17.784

NonHispanic
White
22.957

NonHispanic
Black
20.946

Other Race - Including
Multi-Racial
19.235

30

17.562

23.853

23.668

19.776

12.003

5

20.708

10

15.358

15

18.109

20

22.204

25

8.811

Concentrations in PPB

Distribution of DL-PCB Concentrations Given Genders &
Ethnicities

0

Genders & Ethnicities

Figure 37. Comparison of average dl-PCB concentrations among gender and ethnicities.
Difference in average DL-PCB concentrations is significant, among genders & ethnicities; pvalue <0.05. According to Tukey’s test, a comparison of average DL-PCB concentrations of
White_Male v. Mexican_Male, and Black_Male v. Mexican_Male groups were significant and a
comparison of average DL-PCB concentrations of Black_Female v. Mexican_Female, and
White_Female v. Mexican_Female groups were significant.
Table 46. Comparison of average dl-PCB concentrations among gender and ethnicities.
Ethnicity
Mexican_Male
OtherHispanic_Male

Concentrations,
ng/g lipids
8.811
15.358
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Table 46. (Continued).
Ethnicity

Concentrations,
ng/g lipids
Black_Male
18.109
OtherRace/Multiracial_Male
20.708
Mexican_Female
12.003
OtherHispanic_Female
19.776
White_Female
23.668
Black_Female
23.853
OtherRace/Multiracial_Female 17.562

Concentrations in PPB

Distribution of DL-PCB Concentrations Given
Males & Ethnicities
25
20
15
10
5
0

22.204
15.358

18.109

20.708

8.811

Males & Ethnicities

Figure 38. Comparison of average dl-PCB concentrations among males and ethnicities.
According to Tukey’s test, a comparison of average DL-PCB concentrations of White_Male v.
Mexican_Male, and Black_Male v. Mexican_Male groups were significant.
Table 47. Comparison of average dl-PCB concentrations among males and ethnicities.
Ethnicity
Concentrations,
ng/g lipids

Mexican_
Male
8.811

OtherHispanic_
Male
15.358

White_M
ale
22.204

Black_M
ale
18.109

OtherRace/Multiracia
l_Male
20.708
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Distribution of DL-PCB Concentrations Given Females &
Ethnicities
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30
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Figure 39. Comparison of average dl-PCB concentrations among females and ethnicities.
According to Tukey’s test, a comparison of average DL-PCB concentrations of Black_Female v.
Mexican_Female, and White_Female v. Mexican_Female groups were significant.
Table 48. Comparison of average dl-PCB concentrations among females and ethnicities.
Ethnicity
Concentrations,
ng/g lipids

Mexican
_Female
12.003

OtherHispanic_Fe
male
19.776

White_Fe
male
23.668

Black_Fem
ale
23.853

OtherRace/Multiracial_
Female
17.562
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4.3.3 Logistic Regression Statistics
Odds of Being Overweight Based on Demographics & DL-PCBs
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Figure 40. Odds of being overweight in relation to blood concentration of dl-PCBs. From a
logistic regression model containing Gender, Age, Ethnicity and Quartiles as exposure variables
and Overweight BMI as the outcome, Ethnicity and LDL Cholesterol (High vs Low) differences
are significant in increasing the odds of being overweight. Most interestingly is the 1.063 odds
ratio produced for Other Hispanic (non-Mexican) Vs. Mexican, 1.075 odds ratio produced for
Other Race Vs. Mexican categories, and 1.353 odds ratio produced for High LDL Cholesterol
Vs. High LDL Cholesterol.
Table 49. Odds of being overweight in relation to blood concentration of dl-PCBs.
Effect

Odds Ratio

Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1

0.854
1.023
1.239
1.353
1.075

95% Confidence
Intervals
0.589
1.239
1.008
1.037
0.768
1.999
0.778
2.352
0.417
2.769

0.873
0.823
1.063
0.434

0.453
0.503
0.345
0.184

1.682
1.348
3.272
1.027
89

Table 49. (Continued).
Effect

Odds Ratio

Quartile 3 v. 1
Quartile 2 v. 1

0.658
0.663

95% Confidence
Intervals
0.319
1.358
0.331
1.326

Odds of Being Obese Based on Demographics & DL-PCBs
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Figure 41. Odds of being obese in relation to blood concentration of dl-PCBs. No comparisons
yielded significant odds of obese BMI.
Table 50. Odds of being obese in relation to blood concentration of dl-PCBs.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American

Odds
Ratio
1.379
0.991
1.600
1.129
0.331

95% Confidence
Intervals
0.941
2.020
0.976
1.005
0.989
2.589
0.633
2.012
0.112
0.980

1.287
0.575

0.685
0.350

2.418
0.943
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Table 50. (Continued).
Effect

Odds
Ratio
0.477
1.395
1.405
0.978

Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

95% Confidence
Intervals
0.140
1.632
0.591
3.293
0.679
2.906
0.488
1.958

4.4 Phthalates
4.4.1 Frequency Distributions

Frequency Distribution of Phthalate
Concentration Ranges Per Quartile
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Figure 42. Frequency distribution of the sum of phthalates per quartile range.
Table 51. Frequency distribution table of the sum of phthalates per quartile range.
Sum of Phthalates (Quartiles)
Concentration Range
Frequency
Q1 (9-183.42)
565
Q2 (183.49-369.54 )
566
Q3 (369.77 -776.19)
566
Q4 (776.94 -31734)
566

Percent
100.00%
0.00%
0.00%
0.00%

Min
Max
9.282631811 31733.40514
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Table 52. Frequency distribution table of age ranges cross-referenced with total phthalate
quartiles.
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Table 53. Frequency distribution table of gender cross-referenced with total phthalate quartiles.

Table 54. Frequency distribution table of ethnicities cross-referenced with total phthalate
quartiles.
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4.4.2 Comparative Statistics
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Figure 43. Comparison of average phthalate concentrations among age groups, in years.
Difference in mean Phthalate concentrations between age groups were significant; p-value <0.05
Table 55. Comparison of average phthalate concentrations among age groups, in years.
Age Group, in years

12 to 18

19 to 30

31 to 50

51 to 84

Concentrations, in ng/g
lipids

791.161

898.867

826.693

688.263

85 and
Above
397.113
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Average Urinary Phthalate Concentrations
Based on Gender in '03-'04 NHANES Survey
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Figure 44. Comparison of average phthalate concentrations among genders. Difference in mean
phthalate concentrations between genders were insignificant; p-value >0.05.
Table 56. Comparison of average phthalate concentrations among genders.
Gender
Concentrations, in ng/g
lipids

Male
835.662

Female
727.169
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Average Urinary Phthalate Concentrations
Based on Race/Ethnicity in '03-'04 NHANES
Survey
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Figure 45. Comparison of average phthalate concentrations among ethnic groups. Difference in
mean Phthalate concentrations between races were significant; p-value <0.05.
Table 57. Comparison of average phthalate concentrations among ethnic groups.
Ethnicity

Mexican
American

Other
Hispanic

Concentrations, in
ng/g lipids

763.812

1086.998

NonHispanic
White
626.326

NonHispanic
Black
1061.037

Other Race - Including
Multi-Racial
552.166
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Distribution of Phthalate Concentrations Given Genders & Ethnicities
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Figure 46. Comparison of average phthalate concentrations among gender and ethnicities.
According to Tukey’s test, a comparison of average phthalate concentrations of
OtherHispanic_Male and Black_Male groups was significant and a comparison of average
phthalate concentrations of OtherHispanic_Female and White_Female, Black_Female and
Mexican_Female, Black_Female and White Female were significant.
Table 58. Comparison of average phthalate concentrations among gender and ethnicities.
Ethnicity

Concentrations,
in ng/g lipids
Mexican_Male
852.102
OtherHispanic_Male
920.440
White_Male
711.763
Black_Male
1060.784
OtherRace/Multiracial_Male
567.649
Mexican_Female
679.306
OtherHispanic_Female
1244.552
White_Female
547.704
Black_Female
1061.277
OtherRace/Multiracial_Female 540.984
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Concentrations in PPB

Distribution of Phthalate Concentrations
Given Males & Ethnicities
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Figure 47. Comparison of average phthalate concentrations among males and ethnicities.
According to Tukey’s test, a comparison of average phthalate concentrations of
OtherHispanic_Male and Black_Male groups was significant.
Table 59. Comparison of average phthalate concentrations among males and ethnicities.
Ethnicity
Concentrations,
in ng/g lipids

Mexican_M
ale
852.102

OtherHispanic_
Male
920.440

White_M
ale
711.763

Black_M
ale
1060.784

OtherRace/Multiracial
_Male
567.649
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Distribution of Phthalate Concentrations
Given Females & Ethnicities
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Figure 48. Comparison of average phthalate concentrations among females and ethnicities.
According to Tukey’s test, a comparison of average phthalate concentrations of
OtherHispanic_Female and White_Female, Black_Female and Mexican_Female, Black_Female
and White Female were significant.
Table 60. Comparison of average phthalate concentrations among females and ethnicities.
Ethnicity
Concentration
s, in ng/g lipids

Mexican_Fe
male
679.306

OtherHispanic_F
emale
1244.552

White_Fe
male
547.704

Black_Fe
male
1061.277

OtherRace/Multiracial
_Female
540.984
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4.4.3 Logistic Regression Statistics

Odds of Being Overweight Based on Demographics & Phthalate
Concentration
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Figure 49. Odds of being overweight in relation to urinary concentration of phthalates.
Table 61. Odds of being overweight in relation to urinary concentration of phthalates.
Effect

Odds Ratio

Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

0.715
1.010
1.319
1.304
0.666

95% Confidence
Intervals
0.514
0.994
1.001
1.019
0.869
2.001
0.790
2.152
0.263
1.685

0.825
0.967
1.857
1.273
1.192
1.334

0.489
0.636
0.710
0.785
0.745
0.847

1.392
1.472
4.859
2.067
1.907
2.099
100

Odds of Being Obese Based on Demographics & Phthalate
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Odds Ratio
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Figure 50. Odds of being obese in relation to urinary concentration of phthalates.
Table 62. Odds of being obese in relation to urinary concentration of phthalates.
Effect
Female v. Male
Age in Years
High v. Low Triglycerides
High v. Low LDL
OtherRace & Multiracial v. Mexican
American
NonHispanic Black v. Mexican American
NonHispanic White v. Mexican American
Other Hispanic v. Mexican American
Quartile 4 v. 1
Quartile 3 v. 1
Quartile 2 v. 1

Odds
Ratio
1.810
1.002
2.170
0.609
0.340

95% Confidence
Intervals
1.297
2.525
0.993
1.011
1.427
3.298
0.355
1.047
0.127
0.913

1.248
0.675
0.496
1.702
1.127
1.089

0.761
0.446
0.167
1.057
0.705
0.690

2.048
1.024
1.470
2.740
1.800
1.721
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4.5 Comparison of Analytes

Coefficient of Determination For Age: PBDEs &
DL-PCBs
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Figure 51. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among
age-groups. Approximately 22.5% of the total variation in y can be explained by the linear
relationship between x and y (as described by the regression equation). A positive moderate
association exists between concentrations of PBDEs and dl-PCBs among age groups; R=0.47.
Finally, p-value<0.05; there is a significant difference in the average concentrations of PBDEs in
comparison to dl-PCBs’, among age groups.
Table 63. Comparison of average PBDE and dl-PCB concentrations among age-groups.
Age
Groups
1
2
3
4
5

Ages

Mean PBDE Concentrations (ppb) Mean dl-PCB
Concentrations (ppb)
12 to 18
76.134
5.652
19 to 30
81.089
6.578
31 to 50
78.433
15.025
51 to 84
84.654
39.665
85 and Above 104.898
75.020
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Coefficient of Determination For Gender:
PBDEs & DL-PCBs
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Figure 52. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among
genders. Approximately 3.1% of the total variation in y can be explained by the linear
relationship between x and y (as described by the regression equation). A negative but very weak
association exists between concentrations of PBDEs and dl-PCBs among genders; R=0.17.
Finally, p-value>0.05; there is no significant difference in the average concentrations of PBDEs
in comparison to dl-PCBs’, among gender groups.
Table 64. Comparison of average PBDE and dl-PCB concentrations among genders.
Gender
Groups

Genders

Mean PBDE
Concentrations (ppb)

1
2

Male
Female

93.780
68.599

Mean dl-PCB
Concentrations
(ppb)
17.987
20.635
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Coefficient of Determination For Ethnicities:
PBDEs & DL-PCBs
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Figure 53. Comparison of average PBDE (in blue) and dl-PCB (in red) concentrations among
ethnicities. Approximately 0.7% of the total variation in y can be explained by the linear
relationship between x and y (as described by the regression equation). A positive but very weak
association exists between concentrations of PBDEs and dl-PCBs among ethnicities; R=0.08.
Finally, p-value<0.05; there is a significant difference in the average concentrations of PBDEs in
comparison to dl-PCBs’, among ethnic groups.
Table 65. Comparison of average PBDE and dl-PCB concentrations among ethnicities.
Ethnic
Groups

Ethnicities

Mean PBDE
Concentrations (ppb)

1
2
3
4
5

Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other
Race/MultiRacial

71.607
59.555
85.321
86.671
64.954

Mean dl-PCB
Concentrations
(ppb)
10.477
17.784
22.957
20.946
19.235
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4.6 Summary of Results
Summary of PBDE Results
•

Mean PBDE concentrations are significantly different among genders
o For sum, BDE-47, BDE-99

•

Mean PBDE concentrations are not significantly different among age groups,
ethnicities
o For sum, BDE-47, BDE-99

•

Based on categorical analysis,
o Ethnicity is the only significant predictor of overweight BMI
o Although, confidence intervals were generally large
o No significant results were found for obesity analyses

•

The difference in PBDE blood concentrations was insignificant when accounting
for genders and ethnicities.

Summary of dl-PCB Results
•

Mean PCB concentrations are significantly different among age groups and
ethnicities

•

Mean PCB concentrations are not significantly different among genders

•

Based on categorical analysis
o Ethnicity and LDL cholesterol are predictors of overweight BMI
o Although, confidence intervals were generally large
o No significant results were found for obesity analysis
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•

The difference in PCB concentrations were significant among gender and
ethnicities, males and ethnicities, and females and ethnicities.

Summary of phthalate Results
•

Mean Phthalate concentrations are significantly different among age groups and
ethnicities.

•

Mean Phthalate concentrations are not significantly different among genders.

•

Based on categorical analysis,
o Ethnicity is the only significant predictor of overweight BMI.
o Although, confidence intervals were generally large.
o No significant results were found for obesity analysis.

•

The difference in Phthalate concentrations were significant among gender and
ethnicities.

Summary of Analyte Comparison Results
•

Mean concentrations among age groups, in parts per billion, differed
significantly between PBDEs and dl-PCBs.

•

Mean concentrations among genders, in parts per billion, did not differ
significantly between PBDEs and dl-PCBs.

•

Mean concentrations among ethnicities, in parts per billion, differed
significantly between PBDEs and dl-PCBs.
o Blood serum concentrations of PBDEs was generally higher than dlPCBs in analyses of age groups, genders and ethnicities.
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Chapter 5
Discussion
5.1 Evaluation of Research Hypotheses
The proposed hypotheses of this dissertation research will be examined below, to determine how
well the results of this study supported the overall objectives of this research:

Hypothesis 1: Biomonitoring data obtained from the National Health and Nutrition Examination
Survey indicates the presence of background biomarkers of PBDE, dl-PCB, and phthalate
exposure in individuals from a sample of the general population.

Through the analyses that were conducted using the Demographic Variables & Sample
Weights, Phthalates, and Dioxins, Furans, & Coplanar PCBs, there is evidence that PBDE, dl-PCB
and Phthalate biomarkers are present in a sample of the US population. However, one must
remember that the metabolism of pollutants can vary among study participants (Manno et al.,
2010). The latter has an impact on the reported concentrations of each analyte. In addition, one
should consider the impact of dilution on reported analyte concentrations, especially in the case of
urinary phthalates.

Hypothesis 2: Due to the bioaccumulative properties of PBDEs in the human body, increasing
PBDE concentrations is significantly associated with increasing with age groups.
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•

Due to the bioaccumulative properties of dl-PCBs in the human body, increasing dl-PCB
concentrations is significantly associated with increasing with age groups.

•

Due to the bioaccumulative properties of phthalates in the human body, increasing
phthalate concentrations is significantly associated with increasing with age groups.

A comparison of the average concentrations of PBDEs among age groups reveal that
concentrations of the sum of PBDEs, BDE-47, and BDE-99 are not significantly associated with
increasing age groups. The opposite results were found in an analysis of the distribution of dl-PCB
and phthalate concentrations among age groups. It is not known why such differences in
distributions exist since all three compounds are known to accumulate in the body over time. In
the case of dl-PCBs, an exponential increase in concentration with increasing age groups was
observed which supports the notion that these contaminants have a relatively long half-life in
comparison to PBDEs. In the case of phthalates, urinary concentrations generally decrease with
age. Furthermore, participants aged 85 or older have urinary concentrations that are, on average,
lower in comparison to other age groups. Additionally, it should be noted that the age groups were
arbitrarily divided. Hence, different conclusions and trends could have been generated if much
different age groups were selected. Also, since the dataset is limited to ages 12 – 85 years, it is not
known whether different conclusions would have been generated if the NHANES survey of these
contaminants included individuals of a broader age range (e.g., including participants younger than
12 years old).

Hypothesis 3: Since PBDEs are ubiquitous in the environment, the average concentrations of its
biomarkers are homogeneous across other sample subgroups including genders, ethnicities, and,
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genders and ethnicities; indicating that these subgroups are not at an increased risk of a negative
health outcome.
•

Similarly, average dl-PCB concentrations are homogeneous across other sample
subgroups including genders, ethnicities, and, genders and ethnicities; indicating that
these subgroups are not at an increased risk of a negative health outcome.

•

Similarly, average phthalate concentrations are homogeneous across other sample
subgroups including genders, ethnicities, and, genders and ethnicities; indicating that
these subgroups are not at an increased risk of a negative health outcome.

Concerning the analysis of other demographic categories, including gender, ethnicities and
gender with ethnicities significant differences were observed for all analytes of interest. First, the
average PBDE concentrations reported for the sum of PBDEs, BDE-47 and BDE-99 were
significantly different among genders. In fact, males consistently had significantly higher average
concentrations of the sum of PBDEs, BDE-47 and BDE-99. This is likely due to toxicokinetic
(e.g., absorption, metabolism and elimination) differences among genders. The opposite was found
in the case of dl-PCBs and phthalates. Once again it is not known why PBDEs are distributed
differently than dl-PCBs and phthalates, among genders. In fact, a similar difference was found
when analyzing the concentrations of these analytes among ethnicities. Specifically, the average
concentrations of the sum of PBDEs, BDE-47, and BDE-99 were not significantly different among
ethnicities. On the other hand, significantly different concentrations of dl-PCBs and phthalates
were observed among ethnicities. Moreover, based on an analysis of the average concentrations of
PBDEs, BDE-47 and BDE-99, there is no significant difference among genders and ethnicities
(e.g., Black males v. Mexican American females). The latter supports part of the above-listed
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hypothesis. However, when the analyses were conducted for the other contaminants, the opposite
conclusions were found. Specifically, the difference in dl-PCB concentrations were significant
among gender and ethnicities, males and ethnicities, and females and ethnicities. Also, the
difference in phthalate concentrations were significant among gender and ethnicities; not for males
and ethnicities, nor females and ethnicities. Tukey’s Test was used to determine which specific
groups had significantly different concentrations for dl-PCBs and phthalates, using a 95%
confidence level. According to Tukey’s test, a comparison of average dl-PCB concentrations of
White_Male v. Mexican_Male, and Black_Male v. Mexican_Male groups were significant and a
comparison of average dl-PCB concentrations of Black_Female v. Mexican_Female, and
White_Female v. Mexican_Female groups were significant. Also, according to Tukey’s Test, a
comparison of average phthalate concentrations of OtherHispanic_Male and Black_Male groups
was significant and a comparison of average phthalate concentrations of OtherHispanic_Female
and White_Female, Black_Female and Mexican_Female, Black_Female and White Female were
significant. The significant outcomes that were discovered in the analyses of dl-PCB and phthalate
concentrations could have been due to the oversampling of minorities through the NHANES
program. As mentioned in the Methods section, the NHANES program oversamples minorities
and the elderly since they tend to have drastically different health statuses and characteristics of
concern, in comparison to non-minorities (CDC, 2012). However, one must note that this
oversampling could lead to an overestimation of true exposure. Thus, the significant differences
of dl-PCB and phthalate concentrations found among age groups, ethnicities, and genders with
ethnicities could have been nullified if elderly and minority groups were not given special
attention. The reported data could be overestimating the actual concentration of the biomarkers
when extrapolating results to the population. In fact, true population levels may be lower than
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those reported in the NHANEs sample (Lebeau, 2012). Finally, as a result of the consistency of
results that have been observed between analytes, one can conclude that PBDEs appear to be
distributed differently among demographic categories in comparison to dl-PCBs and phthalates.
In contrast, when considering the homogeneity or heterogeneity of average dl-PCB and phthalate
concentrations among various demographic categories, significance of results is similar for both
types of compounds. These results suggest pharmacodynamic differences for PBDEs in
comparison to dl-PCBs and phthalates. Correspondingly, these results also suggest possible
pharmacodynamic similarities between dl-PCBs and phthalates.

Hypothesis 4: Blood sample data from the National Health and Nutrition Examination Survey
reveal that the background concentrations of PBDEs do not significantly increase the odds of
obesity nor the odds of being overweight.
a. Blood sample data from the National Health and Nutrition Examination Survey reveal
that the background concentrations of dl-PCBs do not significantly increase the odds
of obesity nor the odds of being overweight.
b. Blood sample data from the National Health and Nutrition Examination Survey reveal
that the background concentrations of phthalates do not significantly increase the
odds of obesity nor the odds of being overweight.

According to a categorical analysis of PBDEs and obesity, PBDE background
concentrations (higher vs. lower quartiles) did not significantly increase participants’ odds of being
obese. In fact, when considering age, gender, ethnicity, LDL cholesterol, triglycerides and PBDE
quartiles in the logistic regression model no results were significant. In the case of overweight
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status, ethnicity was the only significant predictor of overweight BMI. Next, analyses also show
that the background concentrations of dl-PCBs did not significantly increase one’s odd of being
obese or overweight. Ethnicity and LDL cholesterol were the only significant predictors of
overweight BMI, when considering age, gender, ethnicity, LDL cholesterol, triglycerides and
PBDE quartiles in the logistic regression model. Finally, background concentrations of phthalates
did not significantly increase participant’s odds of obesity or of being overweight. Ethnicity was
the only significant predictor of overweight BMI, when considering age, gender, ethnicity, LDL
cholesterol, triglycerides and PBDE quartiles in the logistic regression model. Although, it should
be noted that confidence intervals were generally large in all three sets of categorical analyses.

Hypothesis 5: Due to the similarities of PBDEs and dl-PCBs, average concentrations are not
significantly different among demographic categories.
c. Although distributions of phthalate concentrations can be discussed in relation to
PBDEs, specific comparisons cannot be made due to a difference in measurement units
(ng/g lipids for PBDEs and dl-PCBs vs. ng/mL for phthalates).

First, it should be reiterated that a direct comparison cannot be made between PBDEs and
phthalates because unlike PBDEs and dl-PCBs which were measured in serum and reported in
ng/g lipid, phthalates were measured in urine and reported in ng/mL. In other words, the prior were
reported in weight/weight ratio whereas the latter was reported in weight/volume ratio. Due to
mathematical convention, a direct comparison cannot be made between these two types of units.
As a result, while the distributions of all three analytes were investigated, direct comparative
analyses could only be conducted for the sum of PBDEs and the sum of dioxin-like PCBs. Based
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on paired t-test analyses, the average concentrations of PBDEs were significantly different from
the average concentrations of dl-PCBs, when considering age groups and ethnicities. Next, average
concentrations of PBDEs and dl-PCBs did not significantly differ when considering genders. In
general, PBDE blood serum concentrations were higher than dl-PCBs in analyses of age groups,
genders and ethnicities. These results are likely due to the 1979 ban on polychlorinated biphenyls.
Although PCBs are persistent in our environments and despite their relatively long half-lives, and
ability to accumulate in the body, PBDEs have been the dominant flame retardants of since
(Vonderheide et al., 2008). Hence, their presence in our environments is likely to be much more
pronounced.

5.2 Evaluation of Results
Overall, the average PBDE concentration among participants in the 2003-2004 NHANES
was approximately 81 ng/g lipid with a range of 0.05 (LOD/√2) to 3676 ng/g lipid. These results
are not clearly comparable with those of other studies for several reasons. First, unlike other
studies, the 2003-2004 NHANES survey provides one of the largest samples used to investigate
polybrominated brominate diphenyl ethers. Most comparable studies have much more limited
sample sizes. As a result, investigators often report concentrations that are on generally less than
those found in this dissertation research. The range of reported results are also much different. For
example, according to a study of a sum of 10 PBDEs, Eskenazi and company reported a range of
4.2 to 1379.4 ng/g lipid in maternal serum and 6.9 to 1385.5 ng/g lipid in child serum, in a study
of the neurodevelopment effects of PBDEs (Eskenazi et al., 2013). Investigators in this study and
others often report the median as a measure of central tendency instead of the mean. This also
makes it difficult to compare results of this study with others. Overall, comparisons are difficult to
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make as a result in differences in congeners, statistical tests, sample size, sample medium (e.g.,
blood, milk, food, etc.) and demographic categories considered. Most studies report PBDE
concentrations (in various media) specifically in nursing mothers and children. Thus, the results
of such studies are not representative of the US population.

Nonetheless, Schecter et al. conducted a 2003 study of the PBDE concentrations in
American breast milk compared to women’s breast milk in other countries. Investigators analyzed
13 PBDEs in 47 individual milk samples from Texan nursing mothers, aged 20 to 41 years old.
Investigators reported a range of 6.2 to 419 ng/g lipid and a mean of 73.9 ng/g lipid. Furthermore,
investigators postulate that their results are similar to concentrations found in American blood and
adipose tissue from Indiana and California (including research by Zota et al.) which are 10 to 100
times greater than PBDE concentrations found in France, Germany, and Russia. They also mention
that most of the women were Caucasian. Hence, it may be more appropriate to compare their
results to PBDE concentrations of White_Females in this dissertation research who had a
comparable average PBDE concentration of 74.1 ng/g lipid. It should also be mentioned that since
their research contained participants who were mostly Caucasian, their results are selectively
biased (Schecter et al., 2003).

5.3 Evaluation of Risk
In general, as a result of a lack of information pertaining to the dose, duration, exposure
source and route biomonitoring data can be difficult to assume risk. The National Health and
Nutrition Examination Survey does not provide such information, which can lead due to a
misinterpretation of the results (Centers for Human Health Assessment, 2017; Lebeau, 2012;
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Manno et al., 2010). Regardless of the latter, a reported concentration, even if it were above a
permissible level, would not be sufficient evidence to suggest a health risk. In fact, some
statistically significant results were observed when considering the average sum of PBDE, BDE47 and BDE-99 concentrations among genders. Males had consistently higher levels than females,
in all three analyses. These results could suggest that males may be more at-risk than females to
the potential health effects of PBDEs. However, this conclusion would likely be incorrect since,
not only do measured concentrations not necessitate risk, a specific health outcome may be
dependent on the phenotypic or genotypic characteristics of individuals. Moreover, the measured
background concentrations may not lead to any health effects in the American population. In
addition, although reference doses have been generated for some BDE congeners, such reference
doses cannot be used to predict risk (IRIS, 2003; IRIS, 2004; IRIS, 2008a-d). They are created to
protect people from potential and often unknown health effects.

5.4 Limitations of the Research
This cross-sectional study using the NHANES survey yielded some significant results
among various demographics, depending upon the contaminant of interest. Since risk assessment
is a very important feature of toxicology, a longitudinal study would have been more appropriate
for the assessment of health risks. A major benefit of the latter is that data would be gathered for
the same subjects repeatedly over a period. This would allow us to monitor increases and decreases
in PBDE concentration. On the other hand, the NHANEs cross-sectional study design only
generates a snapshot of PBDE concentrations for different participants. In addition, since the 20032004 NHANES dataset contained the most recent PBDE concentration data among Americans,
this data is relatively dated. It would be useful to analyze recent data. However, NHANES has not
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produced such a dataset since then. Next, it is unknown whether low dose, chronic exposure to
PBDEs can cause adverse health effects. This makes the evaluation of dose-response difficult. As
previously mentioned, minorities and the elderly were oversampled in this research. This may have
introduced sampling bias into the analyses. Furthermore, there were 297 values that were below
the limit of detection. These values were treated by dividing the LOD/√2. Other treatment methods
which could have been used include LOD=0 and LOD/2. The LOD/√2 treatment method was
automatically applied by the CDC for the dl-PCB dataset. Hence, for comparison’s sake, this
method was also used for the other analytes in this dissertation research. It should also be
mentioned that the all analyses for the sum of PBDEs, BDE-47 and BDE-99 were also performed
using the LOD=0 and LOD/2 treatment methods for values that were below the detection limits of
the analytical instruments. No significant differences were found among analyses. Finally, since
electronic waste workers are often addressed as an occupational group with increased exposure to
PBDEs, it would be worthwhile to assess their blood PBDE concentrations in addition to other
demographics. However, these workers could not be categorized using the NHANES occupational
subset due to the use of broad occupational and industry categories. In other words, electronicwaste workers could not be separated from NHANES’ occupational or industry designations.
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Chapter 6
Conclusion
Since the 1979 ban of polychlorinated biphenyls in the United States, production,
importation and usage of polybrominated diphenyl ethers have grown tremendously due their cost
effectiveness as flame retardants. However, PBDEs experienced a similar fate in December of
2013 when their only US manufacturers and importers guaranteed a complete phase out of these
flame retardants. This phase out occurred largely as a result of unsubstantiated public health
concerns based on inconsistent literature.

In fact, research pertaining to the most potential health effects of PBDEs have been very
inconsistent. Most notably, previous studies have investigated measures of obesity in relation to
PBDE exposure with a focus on pediatric populations. As mentioned in the Literature Review, the
only applicable research is from Agay-Shay, Costa and Vuong et al. whose results have been
conflicting at best. Moreover, no other study has focused primarily on the potential effects of
PBDE exposure in relation to obesity and overweight status of American adults.

Therefore, to address current research gaps, this study investigated the human blood
concentrations of PBDEs among demographic categories generated through the 2003-2004
NHANES. Analyses of this representative sample of the American population revealed detectable
concentrations of PBDEs ranging from 0.05 to 3676 ng/g lipid. Among the various demographic
categories that were analyzed, PBDE concentrations per gender yielded the only significant results
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for the sum of PBDEs, BDE-47 and BDE-99. In addition, PBDEs did not lead to a higher odd of
being obese or overweight. These analyses were repeated for dioxin-like polychlorinated biphenyls
and phthalates. In general, analyses of dl-PCBs and phthalates among demographic categories
produced similar significant results which opposed those of PBDE analyses. Overall, no analytes
led to a significant odd of being obese or overweight.
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Appendices
Appendix I – Polybrominated Diphenyl Ethers Sampled
PBDE Congeners in 2003-2004 NHANES
Name of
Congener

Compound

SAS name
(lipidadjusted)

BDE-17

2,2',4tribromodiphenyl
ether
2,4,4'tribromodiphenyl
ether
2,2',4,4'tetrabromodiphenyl
ether
2,3',4,4'tetrabromodiphenyl
ether
2,2',3,4,4'pentabromodiphenyl
ether
2,2',4,4',5pentabromodiphenyl
ether
2,2',4,4',6pentabromodiphenyl
ether
2,2',4,4',5,5'hexabromodiphenyl
ether
2,2',4,4',5,6'hexabromodiphenyl
ether
2,2',3,4,4',5',6heptabromodiphenyl
ether

LBXBR1LA

BDE-28
BDE-47
BDE-66
BDE-85
BDE-99
BDE-100
BDE-153
BDE-154
BDE-183

Limits of
LOD/√2*
Detection
in ppb
(NHANES
Manual)
0.0025
0.00176776695

LBXBR2LA

0.0025

0.00176776695

LBXBR3LA

0.0062

0.00438406204

LBXBR66L

0.0028

0.00197989898

LBXBR4LA

0.0164

0.01159655121

LBXBR5LA

0.007

0.00494974746

LBXBR6LA

0.0025

0.00176776695

LBXBR7LA

0.017

0.01202081528

LBXBR8LA

0.0025

0.00176776695

LBXBR9LA

0.0041

0.0028991378
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*There were 297 values below the limit of detection. These values were divided by the square
root of two and manually inserted into the master dataset.
Appendix II – Dioxin-Like Polychlorinated Biphenyls Sampled
Dioxin-Like PCBs in 2003-2004 NHANES
Name of
Congener
PCB 105
PCB 118
PCB 156
PCB 157
PCB 167
PCB 189
PCB 126
PCB 81
PCB 169

Chemical Name

SAS Name
(Lipid
Adjusted)*
LBX105LA

2,3,3',4,4'Pentachlorobiphenyl
2,3',4,4',5LBX118LA
Pentachlorobiphenyl
2,3,3',4,4',5LBX156LA
Hexachlorobiphenyl
2,3,3',4,4',5'LBX157LA
Hexachlorobiphenyl
2,3',4,4',5,5'LBX167LA
Hexachlorobiphenyl
2,3,3',4,4',5,5'LBX189LA
Heptachlorobiphenyl
3,3',4,4',5LBXPCBLA
Pentachlorobiphenyl
3,4,4',5LBXTC2LA
Tetrachlorobiphenyl
3,3',4,4',5,5'LBXHXCLA
Hexachlorobiphenyl

*The variable named LBX___ provides the analytic result for that analyte. Analytical results
which were below the detection limit, were automatically divided by the square root of 2 by the
CDC. Units were originally in ng/g of lipid; except for PCB 126, PCB 81, PCB 169 which were
originally in pg/g lipid. Their values were converted to ng/g lipid (parts per trillion to parts per
billion). Also, 562 missing values were removed from the total sample.
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Appendix III – Phthalates Sampled
Phthalate Metabolites in 2003-2004 NHANES
SAS Name
for
Metabolite

Compound

URXECP

Mono-2-ethyl-5carboxypentyl
phthalate
Mono-n-butyl
phthalate
Mono-(3carboxypropyl)
phthalate
Monocyclohexyl
phthalate
Mono-ethyl
phthalate
Mono-(2-ethyl5-hydroxyhexyl)
Mono-(2-ethyl)hexyl phthalate
Mono-isobutyl
phthalate
Mono-n-methyl
phthalate
Mono-isononyl
phthalate
Mono-(2-ethyl5-oxohexyl)
Mono-n-octyl
phthalate
Mono-benzyl
phthalate

URXMBP
URXMC1
URXMCP
URXMEP
URXMHH
URXMHP
URXMIB
URXMNM
URXMNP
URXMOH
URXMOP
URXMZP

Typical
Limits of
Detection
in PPB
(NHANES
Lab
Manual)
in ng/mL
or ppb
0.25

LOD/√2*

0.1767766953

0.40

0.2828427125

0.16

0.113137085

0.402

0.284256926

0.264

0.1866761902

0.32

0.22627417

0.90

0.6363961031

0.26

0.1838477631

1.0

0.7071067812

1.54

1.088944443

0.45

0.3181980515

1.68

1.187939392

0.072

0.0509116882

*The variable named URX___ provides the analytic result for that analyte. These values were
divided by the square root of two and manually inserted into the master dataset. Also, 92 missing
values were removed from the sample.
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Appendix IV – Residential Sources of PBDE Exposure
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